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INTRODUCTION 
 
 In modern day clinical practice most of the physicians encounter adverse 
drug reactions in many forms. Nearly quarter of hospitalized patients suffer from 
an adverse drug reaction. Though such reactions are common, comprehensive 
information regarding various parameters assoiated with such drug reactions are 
not available as many cases are either misdiagnosed or  underdiagnosed. With a 
wide range of newer drugs entering the market each day, the possibility of newer 
drug reactions or commoner drug reactions presenting in a different form should 
be considered. 
 
 Most of the times drug reactions are trivial and benign. But it is absolutely 
essential to diagnose the condition and to find out the offending drug to avoid a 
life threatening reaction  in the future. Adverse drug reactions are not confined to 
the skin but can involve multiple organ systems. Adverse cutaneous drug 
reactions range from the trivial maculopapular rash to the potentially fatal toxic 
epidermal necrolysis. There are also no specific  laboratory investigation or 
confirmatory drug testing available to find the offending drug and the diagnosis in 
most instances is purely by clinical judgement.  
 
 Hence all the physicians should have a detailed knowledge of such drug 
reactions, the common offending drugs and prognostic indicators to handle such 
reactions appropriately. 
 
  
Aims & Objectives 
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AIM OF THE STUDY 
 
To assess the following parameters  
1. The epidemiology of adverse cutaneous drug reactions in our set up. 
2. Drugs commonly involved in adverse cutaneous drug reactions. 
3. Various clinical presentations of adverse cutaneous drug reactions. 
4. To correlate the clinical, histological and biochemical investigations in 
adverse cutaneous drug reactions. 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
A drug is defined as a chemical substance, or combination of substances, 
which is administered for investigation, prevention or treatment of symptoms or 
diseases[1].  
 
An adverse drug reaction (ADR) is an undesirable clinical manifestation  
resulting from administration of a particular drug[1].  
 
WHO defines adverse drug reaction as “ a response to a drug that is 
noxious, unintended and occurs at doses normally used in man for prophylaxis, 
diagnosis, or therapy of disease or for modification of physiological function”[2]. 
 
Serious adverse drug reaction is defined as “ any untoward medical 
occurrence that at any dose results in death, requires hospital admission or 
prolongation of existing hospital stay, resulting in persistent or significant 
disability / incapacity, or is life threatening”[3]. 
 
Adverse drug reactions (ADR) are considered a major health problem to 
the individual as well as for the society[4]. ADRs are under reported and are an 
under estimated cause of morbidity and mortality. ADRs are estimated to 
represent the sixth leading cause of death [1]. The cost of managing ADRs can be 
high, whether they occur in the inpatient or in the outpatient setting. ADRs cause 
patients to lose confidence in treating physicians or have negative emotions 
towards them. Patients seek self treatment options, which further precipitate 
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additional ADRs. Hence ADRs should be quickly diagnosed and managed to limit 
the detrimental effects on the patients.  
 
Risk factors for developing an adverse drug reaction[5] include  
- an older age  
- female gender 
- number of drugs taken by the patient and  
- associated renal or hepatic impairment[6].  
- the incidence of most drug eruptions is increased in the setting of 
immunosuppression; e.g. in patients with AIDS (CD4+ <200/ mm3), the 
risk of developing an exanthematous eruption to sulfamethoxazole is 10 to 
50 fold greater than in the general population[7]. This is a paradox as most 
drug reaction are immunologically mediated. 
 
General incidence of ADRs: 
  The incidence of ADRs varies from 6%  to 30%[8,9]. Percentage of patients  
developing an ADR during hospitalization varies in different studies, ranging 
from 1.4 to 44%, although the incidence ranges between 10–20% in most of the 
studies[10 - 12]. Adverse drug reactions constitute 3–8% of admissions in a hospital 
setting[13 - 15]. In patients with an adverse drug event the average extra length of 
hospital stay was 1.9 days, and the average extra cost of hospitalization was 
$1939, observed in one study in the USA[16]. It is estimated that about 1 in 40 
consultations in general practice are because of ADRs[17]. The percentage of 
consultations for ADRs increased from 0.6% in patients aged 0 –20 years to 2.7% 
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in patients aged more than 50 years[18]. Antibiotics, antiepileptics, non steroidal 
anti inflammatory drugs (NSAIDs), antitumour agents and anticoagulants were 
the most frequently implicated classes of drugs involved in ADRs[19]. The 
incidence of fatality due to drug reactions among patients is estimated to be 0.1 to 
0.3% [20,21]. Fatality due to allergy occurs at a rate of 0.09 per 1000 cases[22]. The 
actual incidence of ADRs may be even greater, as some ADRs mimic natural 
disease states and thus go undetected and / or unreported. 
 
Classification of Adverse Drug Reactions: 
Adverse reactions can be classified in two broad groups. First type 
is due to exaggeration of an intended pharmacologic action of the drug. eg, 
increased bleeding with anticoagulants or bone marrow suppression with 
antineoplastics. The second type occurs from toxic effects unrelated to the 
intended pharmacologic actions. The latter effects are frequently severe, often 
unanticipated (especially with new drugs) and may result from recognized, and 
also from previously undescribed mechanisms[23].  
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Table 3.1 : Classification of adverse drug reactions 
 
Adverse drug reactions can be labelled under one of the following six 
categories: (WHO 2014)[24,25] 
- certain  
- probable / likely  
- possible (unlikely)  
Type of Reaction Features Examples 
A: Dose related 
    (Augmented) 
Common. 
Related to the 
pharmacologic 
action of the drug – 
exaggerated 
pharmacologic response. 
Predictable. Low mortality. 
Dry mouth with tricyclic 
antidepressants, respiratory 
depression with opioids, bleeding 
with warfarin, 
 digoxin toxicity 
B: Non - dose 
related 
     (Bizarre) 
Uncommon. 
Not related to the 
pharmacologic 
action of the drug. 
Unpredictable. 
High mortality. 
Immunologic reactions: 
anaphylaxis to penicillin 
Idiosyncratic reactions: 
malignant hyperthermia with 
general anesthetics 
C: Dose related and 
    time related 
    (Chronic) 
Uncommon. 
Related to the cumulative 
dose. 
Hypothalamic - pituitary - adrenal 
axis suppression by corticosteroids, 
osteonecrosis of the jaw 
with bisphosphonates 
D: Time related 
     (Delayed) 
Uncommon. 
Usually dose related. 
Occurs or becomes apparent 
sometime after use of the 
drug. 
Carcinogenesis 
Tardive dyskinesia 
Teratogenesis 
Leucopenia with Lomustine 
E: Withdrawal 
    (End of use) 
Uncommon. 
Occurs soon after 
withdrawal 
of  the drug. 
Withdrawal syndrome with opiates 
or benzodiazepines (e.g., insomnia, 
anxiety) 
F: Unexpected         
failure of therapy 
    (Failure) 
Common. 
Dose related. 
Often caused by drug 
interactions 
Inadequate dosage of an oral 
contraceptive when used with an 
enzyme inducer. 
Resistance to antimicrobial agents 
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- conditional 
- unclassified, and  
            -    unassessable / unclassifiable.  
 
Determining the cause of a suspected ADR is a complex process. Many 
patients take more than one drug, and it is difficult to distinguish which agent 
would have caused the ADR. An important step to identify an ADR and 
determining causality is by obtaining an accurate history of patient’s drug list. 
 
It is important to assess 
- the interval  between administration of the drug and onset of drug  
reaction   
- worsening of reaction with repeated or increased dosing (Rechallenge) 
- decrease in the intensity of reaction by reducing the dose of drug or     
discontinuing the drug (Dechallenge) 
- previous similar reactions on exposure to the suspected drug 
- reaction known to occur with long term use of the medication 
- symptoms appearing or worsening when a drug was discontinued 
Answering such questions can help the physician to determine 
causality. 
Several algorithms and probability scales have been developed to assist with 
causality determination. Among those published are 
- the Jones algorithm,  
- the Yale algorithm,  
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- the Karch algorithm,  
- the Begaud algorithm, and a  
- quantitative approach algorithm (Srinivasan 2011).  
 
Two of the most commonly used are the Naranjo ADR Probability Scale and  
Liverpool ADR causality assessment tool, because of their simplicity and time 
efficiency. In the Naranjo ADR Probability Scale, the ADR probability 
classification can be determined by answering 10 questions about the ADR and 
assigning a numeric score to each answer. 
  
          Image 3.1: Naranjo ADR Probability Scale[26] 
 
Liverpool ADR causality assessment tool[27], another commonly used 
method to assist with causality determination is shown below. 
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Image 3.2: Liverpool ADR casualty assessment tool 
 
 
 
Adverse Drug Reactions should be monitored and reported regularly which 
helps in preserving the safety and quality of life for the patient. It also aids in cost 
saving to the patient and the health care institution. By reporting known or 
suspected ADRs, pharmacists, other health care practitioners, and patients can 
assist in identifying patterns and trends, which may lead to increased regulatory 
scrutiny or even the withdrawal of drugs that do not have a favorable risk benefit 
ratio. There are various reporting agencies throughout the world engaged in 
monitoring ADRs. 
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       Table 3.2: Various ADR reporting agencies 
United States Premarketing Clinical Trials 
Postmarketing Surveillance 
The FDA Adverse Event Reporting System 
The Institute for Safe Medication Practices 
The Joint Commission 
MEDMARX 
Canada The Canada Vigilance Program  
Canadian Adverse Reaction Newsletter (CARN) 
UK Yellow Card Scheme  
Drug Safety Update 
India Pharmacovigilance programme(PvPI) 
Global ADR 
Reporting(WHO) 
Uppsala Monitoring Centre in Sweden, through a 
database called “VigiBase” 
 
Pharmacovigilance programme (PvPI): 
Pharmacovigilance involves the study of drug related injuries and making 
recommendations for warning or withdrawal of  pharmaceutical agents. This 
encompasses the understanding , detection, assessment, and prevention of ADRs. 
Pharmacists play a vital role in every step of the pharmacovigilance process, by 
which patients are prevented from undergoing unnecessary procedures or taking 
unwarranted drugs. 
 
 Indian pharmacopoeia commission (IPC), Ghaziabad functions as National 
Co ordination Centre (NCC) for pharmacovigilance programme in India. In 
various medical institutions in India about 250 ADR monitoring centres (AMC) 
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were established to monitor and collect reports about ADRs, under NCC - 
PvPI[28]. 
 
 Suspected ADR reporting forms are available in the website of  IPC in 10 
vernacular languages. ADRs can also be reported via PvPI helpline number, 
18001803024  on weekdays from 9 am to 5.30 pm[28]. 
 
Adverse cutaneous drug reactions: 
Definition:  
An adverse cutaneous drug reaction (ACDR), also called as “Drug 
eruption”,  is any undesirable change in the structure or function of the skin, its 
appendages or mucous membranes and it encompass all adverse events related to 
drug eruption, regardless of the etiology[29]. 
 
 Adverse cutaneous drug reactions (ACDRs) are the most frequent 
manifestation of all adverse drug reactions accounting for about 24% in one study 
and 29% in another study[30,31]. The incidence of drug eruptions in most estimates 
are inaccurate, as many mild and transitory eruptions are not recorded, and skin 
disorders are sometimes falsely attributed to drugs. The incidence of ACDR in 
developed countries range from 1 to 3% among in patients[32,33], whereas in 
developing countries such as India, some studies peg it to 2 - 5% of the 
inpatients[34 - 37]. According to  World Health Organization (WHO) approximately 
2% of all ACDRs are considered “serious” and only very few are fatal [5,38]. 
Relative incidence rate of ACDR among new patients attending dermatology OPD 
were found to be 2.05 per 1000 in a study by Abanti S et al[39].  
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ACDRs can be classified based on  
1. Pathomechanism and  
2. Clinical severity. 
Based on pathomechanisms ACDRs can be classified  into non 
immunologic (75 - 80%) and immunologic (5 - 10%). The remaining 20 - 25% of 
adverse drug events are caused by unpredictable effects that may or may not be 
immune - mediated (Table 3). 
 
Table 3.3 :  Classification of ACDRs based on pathomechanism 
Non immunological Immunological 
(unpredictable) 
Predictable Unpredictable  IgE  dependent drug 
reactions 
 Immune complex 
dependent drug 
reactions 
 Cytotoxic drug  
induced reactions 
 Cell  mediated 
reactions 
 Overdosage 
 Side effects 
 Cumulation 
 Delayed toxicity 
 Facultative effects 
 Drug interactions 
 Metabolic alterations 
 Teratogenicity 
 Non  immunological 
activation of effector 
pathways 
 Exacerbation of 
disease 
 Drug induced 
chromosomal 
damage 
 Intolerance 
 Idiosyncrasy 
Miscellaneous 
 Jarisch   Herxheimer 
reactions 
 Infectious 
mononucleosis  -  
ampicillin reaction 
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Pathogenesis of  adverse cutaneous drug reactions: 
Non immunologic mechanisms: 
Overdose: 
- Predictable clinical manifestations  
- Exaggeration of the drug’s pharmacologic actions. 
- Due to prescribing error or deliberate excess by the patient.  
- Can be observed in patients with usual doses if they have differing rates 
of absorption, metabolism or excretion.  
- Example  -  methotrexate toxicity in elderly patients with reduced renal 
function. 
Pharmacologic side effects: 
- Undesirable or toxic effects  
- Cannot be separated from the desired pharmacologic actions . 
- Example -  chemotherapeutic agents targeting rapidly dividing cells 
causing alopecia, mucositis and pancytopenia. 
Cumulative toxicity: 
- Prolonged exposure to a medication. 
- Example -  Accumulation of  silver, minocycline and amiodarone 
within the skin leading  to distinctive discoloration of the skin.  
Delayed toxicity: 
- Toxic, dose dependent effect  
- Occurs months to years after the discontinuation of a medication.  
-    Examples - arsenic and the development of squamous cell carcinomas            
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Drug – drug interactions: 
- Interactions between two or more drugs administered simultaneously 
-    Occurs at several different steps:  
(1) intestinal drug interactions - tetracycline and calcium 
(2) displacement from binding proteins or receptor sites - 
methotrexate and sulfonamides 
(3) enzyme stimulation or inhibition -  cyclosporine and azoles 
(4) altered drug excretion - methotrexate and probenecid    
Alterations in metabolism: 
- Induce cutaneous changes by their effects on the nutritional or 
metabolic status of the patient.  
- eg - Bexarotene may induce severe hypertriglyceridemia and eruptive 
xanthomas, while isoniazid may be associated with pellagra like 
changes. 
Exacerbation of disease: 
- Exacerbation of  pre existing dermatologic disease. 
- Example - Androgens in patients with acne vulgaris, lithium and 
interferon in patients with psoriasis. 
Facultative effects:  
- Drug induced alterations in skin or mucous membrane flora.  
- Example - Antibiotics that destroy Gram positive bacteria, allow the 
multiplication of resistant Gram negative species. 
- Pseudomembranous enterocolitis after clindamycin 
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Teratogenicity and other effects on the fetus: 
- Drug induced developmental malformations during the period of 
organogenesis 
- Example - thalidomide , retinoids , cytotoxic drugs 
- Fetal damage in later pregnancy . Eg - warfarin, phenytoin, steroids , 
diethylstilbesterol 
 
Non immunological activation of effector pathways: 
(anaphylactoid reactions) 
- Release mast cell mediators directly and produce urticaria or angio 
oedema, Eg - opiates, codeine 
- Activate complement by an antibody independent mechanism – radio 
contrast media 
- Amplified mast cell degranulation and enhanced biosynthesis of 
lipoxygenase products eg.NSAIDS 
- May potentiate bradykinin activity , Eg.ACE inhibitors 
 
Immunological mechanisms: 
IgE dependent (type I) drug reactions:  
Urticaria and Anaphylaxis:[40] 
  Polyvalent drug protein conjugates              specific IgE molecules 
 on sensitized tissue mast cells/circulating basophil leukocytes   
release of chemical mediators (histamine, eosinophil chemotactic factor of 
anaphylaxis,  leukotriene C4/prostaglandin D2, pro inflammatory cytokines)[41]  
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            effects on target tissues ( skin, respiratory, gastrointestinal and/or 
cardiovascular systems)  
Interleukin -5 (IL-5) and eotaxin             activation and recruitment of 
eosinophils  drug-induced cutaneous eruptions[42].   
Eosinophil degranulation             release of pro inflammatory mediators[43]            
dilatation   and increased permeability of small blood vessels  
oedema and hypotension, bronchiolar smooth muscle contraction, excessive 
mucus secretion, and chemotaxis of inflammatory cells (polymorphs/ 
eosinophils). 
Clinically presents as pruritus, urticaria, laryngeal oedema, bronchospasm 
and  anaphylactic shock with hypotension and possibly death in severe cases. 
Immediate reactions occurs within minutes of drug administration. Accelerated 
reactions  occurs within hours or days, and are generally urticarial but may present 
with laryngeal oedema. Penicillins are the commonest cause of IgE dependent 
drug eruptions. 
 
Antibody-mediated (type II) drug reactions 
Binding of antibody to cells  complement mediated cytolysis    cell 
damage . 
Classical examples of immune complex formation:  
1. Drug (apronalide) as hapten    bound to the surface of a cell (platelets) 
with IgG class antibody     subsequent complement fixation    purpura  
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2. Antibodies to quinidine  -  platelet conjugates[44,45]      
  thrombocytopenic purpura.  
 
Immune complex dependent (type III) drug reactions: 
Urticaria and anaphylaxis: 
Immune complexes     activation of  complement cascade   formation 
of anaphylatoxins ( C3a and C5a)     triggers release of  mediators from mast 
cells and basophils    urticaria or anaphylaxis. 
Serum sickness:  
Persistence of a drug antigen in the circulation for long duration    
synthesis of IgG or IgM class antibodies      circulating antibody antigen 
immune complexes. 
Serum sickness occurs when there is slow removal of persistent immune 
complexes by the mononuclear phagocyte system. Symptoms and signs develop 
about 6 days or more after drug administration. Clinically manifest as  fever, 
arthritis, oedema, nephritis, neuritis, and an urticarial or papular rash. 
 
Usually seen in  
1. serum therapy     --    large doses of heterologous antibody(horse antiserum 
for the treatment of diphtheria).  
2. antilymphocyte globulin therapy [46].  
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Vasculitis[47 - 49]: 
  Drug induced immune complexes play a part in the pathogenesis of 
cutaneous necrotizing vasculitis.  
                   Immune complexes   
 
 
Deposition on vascular endothelium        interaction with platelets via  Fc receptor  
 
Activation of the complement cascade                     platelet aggregation 
 
Generation of anaphylatoxins C3a and C5a           microthrombus formation 
 
chemotactic for basophils and mast cells.  
 
vasoactive amines and pro inflammatory cytokines release  
 
increased vascular permeability and neutrophil chemotaxis  
 
release of lysosomal enzymes by neutrophils  
 
Local inflammation.  
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These events lead to the histological appearance of leukocytoclastic 
vasculitis. Direct immunofluorescence ( DIF ) staining of skin biopsies shows 
deposition of immunoglobulins and complement in and around blood vessel walls. 
Examples include  LE syndrome caused by  
1. Hydralazine 
2. Hydroxylamine metabolite of procainamide  
Arthus reaction: 
The Arthus reaction is a localized form of immune complex vasculitis.  
Sensitized individual with circulating precipitating antibodies( IgG1 class) 
 
ID or SC  injection of antigen(vaccine) 
 
Local immune complex formation 
 
Cascade of events locally (as in vasculitis described above) 
 
Erythema, oedema, haemorrhage and occasionally necrosis at the injection site 
(peak at 4–10 hrs, then gradually wanes) 
Cell mediated (type IV) reactions 
`The role of delayed type cell mediated immune reactions in  variety of 
cutaneous drug allergy has recently been elucidated[50 - 55]. These include 
morbilliform rashes, fixed drug reactions, lichenoid reactions, LE-like reactions, 
DRESS syndrome, Erythema multiforme and SJS/TEN. 
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Involvement of  immune system of skin in cell mediated drug eruptions 
have been reviewed[50]. Drug specific activated CD4+ or CD8+ T cells are seen in 
circulation in patients with acute  allergy to allopurinol, carbamazepine, 
paracetamol, phenytoin & sulfamethoxazole[56]. 
 
 Predominant CD8+ T cell activation and predominant activation of CD4+ 
cells are associated with more severe (bullous) skin lesions / liver involvement 
and  maculopapular reactions respectively[57,58]. In drug induced exanthems drug 
specific T - cell clones contained heterogeneous T - cell subsets with distinct 
phenotypes (CD4+ > CD8+ ,perforin and granzyme B +) and cell functions ( IL 5 
production, interferon - γ (IFN - γ) production and cytotoxic potential)[59,60]. 
 
In  drug induced maculopapular and bullous eruptions and patch test 
reactions to betalactam antibiotics, CD8+ T cells predominates in the epidermis 
[61]. These T cells displaying a Th1 like cytokine pattern, are cytotoxic to 
epidermal keratinocytes in lectin induced cytotoxicity assays and  proliferated in 
an antigen and MHC specific manner. In contrast, in patients with penicillin 
induced urticarial exanthems , T - cell lines are predominantly CD4+CD8−, with a 
Th2 cytokine pattern[62]. It has been proposed that T cells producing IL-5 might 
contribute to eosinophilia, whereas cytotoxic CD4+ T cells account for the tissue 
damage. Drug specific T cells , by secreting the IL - 8, contribute to the neutrophil 
infiltration in drug-induced AGEP [63]. In bullous drug eruptions target 
keratinocytes expresses  ICAM -1 which plays an important role in the 
cytotoxicity of epidermal T cells[64]. 
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  Drugs are recognized by drug specific CD4+ and CD8+ T cells through T 
- cell receptors (TCRs) in MHC dependent manner. The role of HLA genes in 
severe drug reactions could be explained by this MHC restriction. Distinct T cell 
functions leading to different clinical phenotypes could be revealed by 
immunohistochemical and functional studies of drug reactive T cells .  
Based on the above mechanisms , delayed type hypersensitivity reactions 
have been re classified into four main subtypes[52,65]: 
A. IVa (Th1/monocyte directed) 
B. IVb (Th2/eosinophil directed)  
C. IVc (CD8+/Fas/perforin/granzyme B directed) and 
D. IVd (IL-8/GM-CSF/neutrophil directed).                                                  
 
Influence of human leukocyte antigen (HLA) types:  
Susceptibility to drug eruptions and association between HLA types has 
been extensively studied [65]. The genetic associations can be drug specific.  
1. Reactions to gold associated with HLADRw3, HLA- DR5 and HLA -B8  
[50-55]. 
2. Penicillamine toxicity associated with HLA phenotypes were as follows[50] 
a.HLA - DR3 and HLA - B8 with renal toxicity;  
b.HLA - DR3, HLA - B7 and HLA - DR2 with haematological 
toxicity; c.HLA - A1 and HLA - DR4 with thrombocytopenia, and  
d.HLA - DRw6 with cutaneous adverse reactions.  
3. Intolerance to tiopronin given for rheumatoid arthritis  seen in DR1 / DR4  
heterozygosity, or the DR5 subtypes DRB1*1102 or DRB1*1201[66]. 
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4. Chinese patients with drug eruptions after allopurinol   
a. positive association with HLA - Aw33 and HLA - B17/Bw58 
b. negative association with the HLA - A2 haplotype[66].  
5. HLA - B*5701 has  been linked with abacavir hypersensitivity[56 - 58].  
6. Caucasian Australians with HLA - DRB1*0101 and high CD4+ T-cell 
counts, Sardinians and Japanese with HLA - Cw8 were predisposed to 
nevirapine hypersensitivity [58]. 
7. Carbamazepine  induced Stevens Johnson syndrome and toxic epidermal 
necrolysis (SJS/TEN) shows  HLA - B*1502 positivity , but not 
carbamazepine induced maculopapular eruption or carbamazepine 
hypersensitivity syndrome[57].  
8. Aspirin sensitive asthma -  HLA - DQw2 [57]. 
9. Hydralazine induced LE - common in females with the HLA-DRw4 
haplotype [62,64].  
10. Fixed drug eruptions to febrazone and trimethoprim –sulfamethoxazole 
were linked to HLA - B22 and HLA - A30 B13 Cw6 respectively[64]. 
 
 Genetic association can also be ethnicity specific – carbamazepine induced 
SJS/TEN associated with B*1502 is seen in Han Chinese from Taiwan and other 
Asian countries but not in whites, due to different allele frequencies [58,59]. These 
studies provide a basis for developing tests to identify individuals at risk for drug 
hypersensitivity[58]. As with HLA - B*5701 genotyping to prevent  abacavir 
hypersensitivity, HLA-B*1502 genotyping in patients from Southeast Asian 
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countries before prescribing  carbamazepine could be valuable in preventing 
carbamazepine induced SJS/TEN.  
 
Adverse cutaneous drug reactions based on clinical presentation: 
 Based on clinical presentation, involvement of mucous membrane, severity 
and systemic involvement adverse cutaneous drug reactions can be classified into  
a. Benign cutaneous adverse drug reactions (constitute the majority) and  
b. Severe cutaneous drug reactions (constitutes 2%)   
  
Benign cutaneous adverse drug reactions: 
Drug induced exanthema: 
Most common adverse cutaneous drug reaction 
 
Synonym: 
 Morbilliform drug eruption, Maculopapular drug eruption 
 
Commonest drugs causing maculopapular eruptions: 
Ampicillin and penicillin, carbamazepine, sulphonamides, phenytoin, non 
steroidal anti inflammatory drugs (NSAIDs), allopurinol. 
 
Pathogenesis: 
Drug specific T cell mediated cytotoxicity 
 
Histopathology[67] 
- Non specific changes seen. Few specific changes are  
a.Apoptotic keratinocytes 
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b.Eosinophils within inflammatory infiltrate 
c.Papillary edema 
d.Vascular changes 
 
     Image 3.3 – Histopathology of drug induced maculopapular rash 
           
 
Clinical features: 
Latency period is 7-10 days but vary between 5-21 days after ingestion of 
offending drug. There is profuse eruption of small pink papules (morbilliform, 
scarlatiniform or rubelliform rash) predominantly over trunk and flexural areas 
with relative sparing of face and pressure areas. Palms and soles can be 
involved.Sometimes the rash can be generalized. Purpuric spots and erosive 
stomatitis may occur. 
  
                                            25 
 
Differential diagnosis:[68] Viral exanthema, DRESS  
Disease course and prognosis: 
 Erythroderma can occur if the offending drug is continued. Spontaneous 
resolution seen in few cases even if offending drug is continued. Rash recurs on 
rechallenge with the drug. 
 
Investigations: 
- To rule out organ involvement as in DRESS syndrome 
- Viral serology/PCR  done to rule out viral infections 
 
Management: 
Offending drug should be stopped. Rashses resolve with desquamation , 
sometimes with post inflammatory  hyper pigmentation. Emollients is all that 
needed in most of the cases. Mid potency topical steroids may be useful to reduce 
pruritis associated with rash. 
 
Fixed drug eruptions: 
First described by ‘Bourns’ in 1889. 
 
Definition: 
It  is a adverse cutaneous drug reaction characterized by well defined 
lesions occurring on the same sites every time the offending drug is taken[69,70].  
 
Most common drugs associated:[71]. 
NSAIDs (25%), paracetamol(24%), co‐trimoxazole (5%) and tetracycline 
(5%).  
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Pathogenesis:[69 - 73] 
FDE is an example of classical delayed type hypersensitivity reaction and  
key mediators are the skin resident T cells. 
 
Effector / memory CD8+ T cells  at the dermo epidermal junction 
in resting FDE lesions 
 
Rechallenge with the drug 
 
Activation and expansion of  resting CD8 + T cells 
 
Release of interferon (IFN) γ and cytotoxic granules 
 
Keratinocyte apoptosis 
 
Regulatory T cells (FOX P3+ T Reg cells) are recruited and inhibit further 
activation of CD8+ T cells by apoptosis of activated T cells 
 
Small population of CD8+ T cells escape apoptosis by the action of  
IL 15 secreted by keratinocytes 
 
Remain as resident cells until further activation 
 
Genetics[74,75]: 
Drug specific HLA associations was seen in few drugs. These include 
cotrimoxazole with HLA ‐ A30  and febrazone induced FDE with HLA ‐ B22  
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Histopathology[69,76]:  
Early lesions -    
a. interface dermatitis reaction pattern 
b. vacuolar degeneration of basal keratinocytes, 
c. dermal oedema   
d. perivascular lymphocytic infiltrate of the upper dermis.  
e. eosinophils may be present.  
 Resolved or healing lesion –  
 pigment‐laden macrophages in the upper dermis  
 
 Image 3.4: Histopathology of fixed drug eruption 
              
 
Clinical features: 
Skin lesions with offending drugs can occur  in all ages but most 
commonly in 40 - 80 years old age group with slight female preponderance. 
Symptoms start within 8 hours of exposure to offending drug for the first time, but 
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as early as 30  minutes on further exposures. Present as well defined round or oval 
erythematous  and edematous patch or plaque.  Later it becomes dusky, 
violaceous and sometimes vesicular or bullous. Usually seen as solitary lesions 
but sometimes as multiple lesions. Lips, genitals, palms and soles are the 
commonly affected sites. Isolated  mucosal FDE is seen in 5% of patients. Lesions 
resolve with post inflammatory hyperpigmentation which usually persists for a 
very long time. 
 
Clinical pattern of FDE: 
FDE of Genitals and lips –NSAIDs 
 FDE of Genitals – tetracycline and  cotrimoxazole 
 FDE of trunk and extremities – metamizole 
 FDE of face – carbocystiene 
 Linear FDE - Cotrimoxazole  
 Non pigmented FDE(Shelley & Shelley in 1987) – Pseudoephedrine,    
piroxicam, paracetamol, thiopental, sorafenib 
 FDE with systemic manifestations – Levamisole 
 
Generalized bullous FDE (GBFDE): 
This is a form of extensive FDE misdiagnosed as toxic epidermal 
necrolysis (TEN)[69,77]. Differentiating features are  
 prior history of similar episodes 
 mucosal surfaces are relatively uninvolved 
  presence of large blisters with intact intervening skin  and  
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 absence of multiple purpuric or target lesions. 
 
Disease course and prognosis: 
 FDE is self limiting with an excellent prognosis. Post inflammatory 
hyperpigmentation  persist for several months. The mortality rate in GBFDE is 
approximately 20%. Patients with GBFDE require the same level of treatment and 
care as for SJS and TEN. 
 
Investigations: 
1.Oral provocation  tests – gold standard 
2.Patch tests – reagents should be placed over sites of previous skin lesions 
rather than upper back. Positive in 50 % patients [78]. 
 
Management: 
Offending drug should be stopped. Topical steroids for  one to few skin 
lesions. For patients with multiple skin lesions systemic steroids can be given. 
Patients with GBFDE should be managed  in ICU as patients with SJS/TEN. 
 
Drug induced urticaria: 
 Second common cause of adverse cutaneous drug reactions. 
 Drug induced urticaria, anaphylaxis and angioedema  can be  
“anaphylactoid” or “pseudoallergic” if they are non immune mediated and 
“allergic” if  IgE mediated. 
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Most common drugs implicated[79,80]: 
 Aspirin, NSAIDs, ACE inhibitors, radio contrast media, local anaesthetics, 
dextran and recently infliximab. Many other drugs are implicated in causing 
urticaria, anaphylaxis and angioedema. 
 
Pathogenesis: 
Mediated by the presence of drug specific IgE antibodies. 
On  exposure to drug, IgE present on mast cell surface cross links 
 
Release of mast cell mediators (histamine) 
 
Vasodilatation, neuronal activation, smooth muscle contraction 
 
Wheal,flare, angioedema, bronchospasm and hypotension 
 
Histopathology: 
- Non specific 
- Vascular and lymphatic dilatation 
- Dermal oedema and  
- Variable perivascular infiltrate consisting of lymphocytes, neutrophils 
and eosinophils 
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Image 3.5: Histopathology of drug induced urticaria                      
 
 
Clinical features 
On the first occasion symptoms  arise within 24–36  hours of drug 
ingestion.Lesions may develop within minutes of rechallenge. Urticaria occurring 
alone is more common than urticaria with angio oedema. Anaphylaxis usually 
develops on second exposure to a drug  and  within minutes to hours of drug 
administration and are often associated with skin or mucosal changes in less 
severe cases.There may be dizziness, skin tingling and redness of the bulbar 
conjunctiva, followed by urticaria, abdominal pain, angio oedema, bronchospasm, 
and vasomotor collapse in severe cases.  More severe reactions and  rapid 
progression  within minutes to cardiac arrest is seen with intravenous 
administration. In patients with  insect sting related and food induced anaphylaxis, 
slow evolution of symptoms are seen [81]. 
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Complications and course of disease: 
 Symptoms resolve within days if offending drug is withdrawn 
immediately and treatment initiated early. Anaphylaxis if not managed properly 
can lead to death. 
 
Investigations: 
Careful history to identify the culprit drug , RAST( Radio Allergo Sorbent 
Assay) to identify drug specific IgE and patch testing. 
 
Management: 
Stop the offending drug. Oral or IV antihistaminics according to severity of 
symptoms. Oral or IV corticosteroids. SC or IM epinephrine in cases of 
anaphylaxis. 
 
Drug induced serum sickness like reactions (SSLI):  
  Characterized by a clinical triad of fever, rash and arthralgias/arthritis. 
 
 Most common drugs implicated: 
Cefaclor ( Most common), penicillins and other β‐lactams, minocycline, 
buproprion, infliximab, rituximab. 
 
Pathogenesis: 
Metabolism and biotransformation of the parent drug to reactive 
metabolites is essential. Inherited defects in the metabolism of these reactive 
intermediates may be a predisposing factor[82]. This is a type III hypersensitivity 
reaction. 
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Reactive drug metabolites (foreign antigen) 
 
Antibodies bind to antigens 
 
Immune complex formation 
 
Deposition in small blood vessels of skin, joints and other organs 
 
Clinical manifestations 
 
Histopathology[83]: 
- Dermal oedema 
- Superficial and deep perivascular infiltrate of lymphocytes, neutrophils 
and eosinophils 
- Vasculitis is usually absent 
 
Clinical features: 
More commonly reported in children with a median latency of 1-13 days. 
Initially manifests as migratory and pruritic urticarial wheals. Sometimes EMF 
like lesions, facial and periorbital edema also seen. Arthralgia, swelling and 
stiffness of small joints of hands and feet is seen. Mucosal and systemic 
involvement is rare in drug induced illness[84,85]. 
 
Disease course and prognosis: 
Symptoms resolve quickly on drug withdrawal. Median duration of rash 
and joint symptoms are 5 and 3 days, respectively[86]. Drug induced SSLI is not 
associated with long term morbidity or sequelae. 
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Investigations:  
Drug provocation testing is safe and reliable 
Management: 
- Withdrawal of culprit drug 
- Symptomatic treatment – Antihistaminics, antipyretics and systemic  
steroids. 
 
Drug induced lichenoid reactions: 
Drug induced LP like lesions are clinically indistinguishable from classical 
LP but can be more severe. Milder form presents as LP like lesions an severe form 
as LE like lesions[87].  
 
Most common implicated drugs: 
For LP like lesions: 
Antimalarials, ACE inhibitors, gold, β‐blockers, mercury amalgam, lithium, 
non steroidal anti inflammatory drugs, methyldopa, pencillamine, quinidine, 
thiazide diuretics.  
 
For LE like lesions: 
ACE inhibitors (e.g. captopril), β‐blockers (e.g. atenolol), calcium channel 
blockers (e.g. diltiazem), fluorouracil (systemic), hydralazine, clobazam, 
isoniazid, statins, sulfasalazine, procainamide, terbinafine, thiazide diuretics. 
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Pathogenesis: 
Autoreactive T cells  are directed against a drug - MHC antigen complex , 
followed by which the  keratinocytes and Langerhans cells are viewed by the 
immune system as ‘non - self’, leading to apoptosis of keratinocytes. 
 
Genetics: 
  73 % of patients with drug induced lupus (Hydralazine) have HLA ‐ 
DR4[88] and  with minocycline  have HLA ‐ DQB1. 
 
Histopathology: 
 Hyperkeratosis, hypergranulosis, sawtooth acanthosis and band‐like 
infiltrate in the superficial dermis. 
 
Histological features attributed to a drug trigger: 
 Less dense but more pleomorphic infiltrate ( including plasma cells and 
eosinophils) 
 Cytoid bodies in the cornified and granular layers 
 Presence of focal parakeratosis and  
 Focal interruption of the granular layer[89] 
 
Only distinguishing histological characteristics of drug induced LP: 
 Higher frequency of  necrotic keratinocytes (in clusters) 
 Plasma cell and eosiniphilic infiltrate [90]. 
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Image 3.6:  Drug induced lichenoid reactions 
 
 
Clinical features: 
Latency period is months to even years after first time exposure to drugs. 
Clinical picture is similar to idiopathic LP with shiny papules and plaques with 
Wickham striae. Drug induced LE lesions are similar to idiopathic SLE with 
lesions in the photoexposed areas. 
 
Disease course and prognosis: 
Resolution of symptoms seen with withdrawal of drug in weeks to months. 
 
Investigations: 
 Skin biopsy to find lichenoid reaction pattern 
 In drug induced LE – ANA positivity seen in 90%  and Anti histone Ab 
seen in 75% of patients. 
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Management: 
Withdrawal of culprit drug. High to very high potent steroids leads to 
resolution of symptoms. Systemic corticosteroids used in very severe disease . 
 
Drug induced acneiform eruptions: 
Constitutes 1% of all adverse cutaneous drug reactions 
 
Most common drugs involved: 
 Hormones -  Corticosteroids, androgens and anabolic steroids, hormonal 
contraceptives, danazol 
 Neuropsychiatric drugs - Tricyclic antidepressants,  lithium , valproate,  
phenytoin,  dantrolene 
 Anti tuberculosis drugs -  Isoniazid,  rifampicin,  ethionamide 
 Halogens -  Iodide, bromide, chlorine 
 Vitamins - Vitamins B1, B6, B12 
 Immunomodulators – Cyclosporin,  sirolimus,  azathioprine 
 Others - Chemotherapeutic agents, epidermal growth factor receptors 
inhibitors, multikinase inhibitors, histone deacetylase inhibitors, 
granulocyte colony stimulating factor 
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Pathogenesis: 
 Corticosteroids – Up regulation of TLR - 2 in involved  
keratinocytes leading  to  predominantly inflammatory lesions[91].  
 Androgenic hormones - stimulates follicular keratinocyte 
proliferation, promote sebaceous gland hyperplasia and increases 
the sebum production[92,93].  
 Sirolimus -  direct toxicity, chemical modification of sebum  and its 
effects on epidermal growth factor receptors (EGFR) 
and testosterone synthesis [94]. 
 
Clinical features: 
Lesions occur after a mean latency period of  7-10 days, but may be longer 
with few drugs. Sudden onset of acneiform lesions without previous history of 
acne. Presence of monomorphic papules and pustules without comedones or cysts 
and predominantly in non seborrhoeic areas are characteristic features. But 
eruptions with EGFR inhibitors are seen in seborrhoeic areas. 
 
Management:  
Symptoms improves on withdrawal of offending drug. Systemic or topical 
treatment as for acne vulgaris may be helpful. 
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Symmetrical drug related intertriginous and flexural exanthema (SDRIFE): 
Definition: 
 A self limiting and benign drug eruption, characterized by symmetrical 
involvement of  the gluteal and intertriginous areas without  systemic 
involvement. 
 
Synonym:  
Baboon syndrome 
Most common implicated drugs: 
Penicillins, cephalosporins, clindamycin, erythromycin, NSAIDs, 
pseudoephedrine, cimetidine, terbinafine 
 
Pathogenesis: 
Type IV delayed type hypersentivity reaction. A form of recall 
phenomenon with preferential trafficking of activated memory T cells to these 
sites, from previous physical/inflammatory insult. 
 
Histopathology: 
Superficial perivascular lymphocytic infiltrate which include neutrophils and 
eosinophils, spongiosis and vacuolar degeneration of the basal cells. 
 
Clinical features: 
Occurs in all age groups with male preponderance. Latency period ranges 
from hours to days after drug intake. Characterised  by papules, pustules, vesicles 
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and sometimes bullae. Palms, soles and face are spared. Diagnosed on the basis of  
following criteria  
 exposure to a systemically administered drug 
 sharply demarcated erythema of the gluteal/perianal area and/or 
V‐shaped erythema of the inguinal area 
 involvement of at least one other intertriginous/flexural location 
 symmetry of the affected areas and 
 absence of systemic symptoms and signs 
 
Differential diagnosis : 
AGEP, inverse psoriasis, intertrigo, Hailey Hailey disease, chemotherapy 
induced  toxic erythema 
 
Investigations: 
Patch testing is positive in 50% of case and oral provocation test in 75% of 
patients. 
 
Management: 
Withdrawal of offending drug and  supportive  measures is all that needed. 
Rarely  topical or systemic steroids are needed  for symptom  resolution. 
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Drug induced pruritus: 
Pruritus can be localized or generalized and constitutes 13.1% of all 
adverse drug reactions. 
 
Common drugs implicated[116]  
Opioids, statins, paclitaxel, antimalarials, granulocyte - macrophage colony 
stimulating factor, interleukin - 2, matuzumab, ACE inhibitors, sulphonylurea 
derivates, NSAIDs. 
 
Pathogenesis: 
Primary (neuronal / central effects) and secondary ( direct skin effects, 
alteration of biochemical profile and unexplained mechanisms)[96] 
 
Clinical features: 
Generalised itching with excoriation and lichenification with a latency 
period of few days. Dermographism is usually absent. 
 
Management: 
  Withdrawal of offending drug. Cooling emollients like 0.5% menthol in 
aqueous solution will be of help  in localized pruritus. Naltrexone, naloxone and 
nalbuphine can be tried in opioid induced pruritus. In severe pruritus , 5HT 
antagonists, serotonin receptor antagonists, D2 receptor antagonists, 
antihiatamines and gapapentin can be tried. In resistant drug induced pruritus 
phototherapy may be of use[97]. 
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Drug induced Pityriasis rosea ( PR ): 
It is an uncommon adverse cutaneous drug reaction but clinically 
resembles pityriasis rosea. Drugs commonly implicated are ACE inhibitors, 
NSAIDs, gold, omeprazole, metronidazole, terbinafine, rituximab and TNF α 
inhibitors. Clinically drug induced PR differs from classical PR by large lesions, 
absent herald patch, significant itching, oral lesions and persistence for a longer 
time. Only differentiating feature in histopathology to classical PR is presence of 
eosinophils. Remission seen within 1 - 2 weeks of withdrawal of offending drug. 
Topical steroids may be required in resistant cases. 
 
Severe cutaneous adverse drug reactions (SCAR): 
  Constitute only 2% of all cutaneous drug reactions, but with very high 
mortality if not managed properly. 
 
Acute generalized exanthematous pustulosis ( AGEP ): 
Definition:  
Acute generalized exanthematous pustulosis (AGEP)  is characterized by 
the rapid appearance of sheets of  sterile non follicular pustules, localized to the 
major flexures, in response to a drug. It is a self limiting and  usually resolves 
without sequelae. 
 
Synonyms : 
• Exanthemic pustular psoriasis 
• Toxic pustuloderma 
• Pustular drug rash 
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Drugs implicated:  
Pristinamycin, aminopenicillins. quinolones, chloroquine and 
hydroxychloroquine, sulphonamides, terbinafine, diltiazem 
 
Pathogenesis: 
Drug specific CD4+ and CD8+ T cells were demonstrated in patch test 
sites and in circulation. CXCL 8 and IL8 producing subsets of T cells have been 
demonstrated in circulation[98].Few subset of patients had IL 36 RN gene mutation 
which encodes for IL 36 Ra receptor antagonist similar to that seen in pustular 
psoriasis. 
 
Histopathology: 
Marked  dermal and epidermal spongiosis, intraepidermal pustules and 
vesicles, neutrophilic  perivascular infiltrate, occasional eosinophils may be  
present and infrequent necrotic keratinocytes seen. 
 
Image 3.7: Histopathology of AGEP 
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Clinical features: 
  Occurs in adults with a mean age of 56 yrs and slight female 
preponderance[99]. 90 % are related to drugs and the remaining associated with 
infections like Mycoplasma pneumoniae [100], coxsackievirus [99], parvovirus B19 
[101,102],  cytomegalovirus (CMV)  and  mercury exposure [103] and spider bites. 
Starts as sheets of sterile non‐follicular pustules arising most commonly in 
the major flexures such as the neck, axillae and inframammary and  inguinal folds  
typically in a background of edematous erythema. Less common features include 
atypical targets, purpura, blisters and vesicles. Mucous membrane involvement is 
rare.  
Systemic manifestations include fever, leucocytosis with neutrophilia and 
eosinophilia, with liver , renal and pulmonary dysfunction  in 18% of patients [104]. 
Rarely agranulocytosis is seen. Roujeau et al diagnostic criteria[105] for AGEP 
include 
• Appearance of hundreds of sterile non follicular pustules at 
flexural sites. 
•  Histopathological changes of spongiosis and epidermal pustule  
•  Fever >38°C. 
•  Blood neutrophil count >7 × 109/L. 
•  Acute evolution. 
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Clinical variant : 
ALEP (acute localized exanthematous pustulosis) - Characterized by 
similar lesions predominantly in a single area , most commonly the neck. First 
described in 2005[106]. 
 
Differential diagnosis: 
Pustular psoriasis, sub corneal pustular dermatoses, DRESS, candidiasis 
 
Disease course and prognosis: 
Has a rapid onset and recovery. Prognosis is excellent with complete 
recovery with desquamation in few days 
 
Investigations: 
Complete hemogram, Biochemical profile, Acute phase reactants , Sepsis 
screening and skin biopsy 
 
Management: 
Corticosteroids based on severity of symptoms. Emollients. Empirical 
antibiotics for suspected infection. IV fluids and hemodynamic monitoring in 
cases with systemic  involvement. 
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Drug reaction with eosinophilia and systemic symptoms ( DRESS): 
Definition: 
Characterized by cutaneous features, a rash and systemic manifestation  
including  haematological and solid organ disturbances [107]. 
 
Synonyms: 
• Drug induced pseudo lymphoma 
• Anticonvulsant hypersensitivity syndrome 
• Drug induced hypersensitivity syndrome (DIHS) 
• Drug induced delayed multiorgan hypersensitivity syndrome 
(DIDMOHS) 
• DRESS was proposed by Bocquet et al. in 1996 
 
Commonest drugs implicated: 
Allopurinol, antiepileptics ( carbamazepine, phenytoin, lamotrigine), 
antibiotics (vancomycin, amoxicillin, minocycline, piperacillin, tazobactam), 
sulpha drugs (sulphasalazine, dapsone, sulphadiazine), furosemide, omeprazole, 
ibuprofen 
 
Pathogenesis:  
Two theories has been put forward [108,109] 
1.Drug specific T cell reaction 
2.Viral reactivation 
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Drug specific T cell reaction:  
Two concepts described were p - i concept and haptenisation theory. 
 
Haptenisation theory: [110] 
  Immunologically neutral molecule(drug)  enzymatic degradation         
protein bound    rendered immunogenic  leading to T cell reaction 
 
p-i concept( pharmacological interaction of drugs with immune receptor):[104] 
Drug binds to protein attached to a MHC molecule or directly into a groove 
in MHC   presented to the T cell  cascade of action by stimulated T cells 
 
Viral reactivation: 
Herpesvirus reactivation has been  demonstrated  in DRESS [105,106]. The 
implicated viruses  includes HHV 6, CMV, Epstein Barr Virus (EBV) and HHV‐7 
[108,111]. Virus reactivation occur in a sequential fashion, with HHV‐ 6 and EBV 
detected earlier in the course followed by HHV‐7 and CMV [112]. Drug induced 
immunosuppressed state, characterized by hypogammaglobulinaemia  facilitates  
reactivation of latent herpesvirus [113].  
 
Genetic susceptibility: 
• HLA B 5701 – Abacavir sensitivity 
• HLA B 5801 – Allopurinol sensitivity 
• HLA B 1502 - Carbamazepine sensitivity in South east asian population 
• HLA B 3101 – Carbamazepine sensitivity in chinese and white population 
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Histopathology:[114] 
Spongiosis, superficial perivascular lymphocytic infiltrate, an eosinophilic 
infiltrate in the dermis, basal cell vacuolar change with the prescence of necrotic 
keratinocytes. Changes resembling erythema multiforme correlates with more 
severe liver dysfunction, and  may be predictive of a higher mortality . 
 
    Image 3.8:  Histopathology of DRESS 
 
 
Clinical features: 
Typical latency period of  2 to 6 weeks between drug ingestion and  onset 
of symptoms. Patient presents with prodromal phase characterized  by  asthenia, 
malaise and fatigue followed by rash with facial swelling .  
 
Rash: 
   Most commonly an urticated papular exanthem accompanied by  cutaneous 
edema. Other presentations include morbilliform eruption, erythroderma and 
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erythema multiforme like features. Characteristic finding in majority of patient is 
head and neck edema. Mucosal involvement is rare.   
 
Lymphadenopathy:  
 Present in two or more sites in majority of patients. 
 
Systemic  involvement :  
Hematological  abnormalities: 
Eosinophilia, pancytopenia (negative predictive factor)[115] , lymphocytosis 
with atypical lymphocytes. Leucopenia, lymphopenia  and  thrombocytopenia also 
noted. 
 
Liver:    
Seen in 70 to 90 percent of cases [100]. Severity varies from mild and  
transient hepatitis to fulminant hepatic failure . Patients with erythema multiforme 
like lesions and associated with minocycline have a higher risk of  severe hepatic 
involvement  . 
 
Renal:   
   Seen in upto 10% of patients especially with allopurinol. Presents with  
proteinuria, and urinary eosinophils. Interstitial nephritis is seen  histologically.  
 
Heart - Pericarditis and myocarditis [116] 
Lung - Pleural effusion, pleuritis  and  acute interstitial pneumonitis .  
Central  nervous system - Seizures, cranial nerve palsy, SIADH[117]. 
GIT  - Diarrhoea, eosinophilic  esophagitis  and  dysphagia  . 
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Endocrine system - Hypothyroidism, hyperthyroidism, pancreatic   insufficiency  
with  type 1 diabetes[118]. 
 
Differential diagnosis:  
Sepsis, AGEP, SJS, TEN, erythema multiforme, angioimmunoblastic  
lymphoma.  
 
Disease course and prognosis :  
    Majority recover fully following  drug withdrawal and management of  
acute episode. Mortality rate is 5 - 10 % with hepatic failure being the commonest  
cause. Organ specific chronic sequelae seen according to the organ involvement in 
acute episode. 
 
Investigations:  
   To rule out organ involvement and to monitor systemic manifestations. 
 
Management:   
Withdrawal of offending  drug, admission in a intensive care unit, IV  
fluids, thermoregulation, supplemental oxygen and topical emollients. 
First line   -  oral prednisolone 1mg/kg/day tapered over 1 to 3 months .  
-   methyl prednisolone  1gm/day for three days [106]. 
Second line   -   Cyclosporine – 2 to 5 mg/kg/day  [119]   
     -   intravenous immunoglobulin  400mg/kg/day for 5 days[120]. 
Third line      -  ECMO, plasmapheresis, rituximab, valgancyclovir, N - acetyl 
                          cysteine [121]. 
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Steven Johnson syndrome / Toxic epidermal necrolysis (SJS/TEN): 
Synonym:  
 Lyell syndrome 
History:  
 First described independently by Steven and Johnson in 1922[107]. Lyell  
coined the term Toxic epidermal necrolysis and described it in 1956[122]. 
Definition: 
Severe mucocutaneous reactions characterized by blistering and epidermal 
sloughing 
Most common implicated drugs 
Allopurinol, Carbamazepine, Lamotrigine, Nevirapine, Oxicam NSAIDs, 
Phenobarbital, Phenytoin, Sulfamethoxazole and other sulfa antibiotics, 
Sulfasalazine 
Pathogenesis[103]  
MHC class I‐restricted drug presentation 
 
Drug‐induced cytotoxic T lymphocytes 
 
Cytokines and soluble factors 
(tumour necrosis factor‐α, interferon‐γ, and inducible nitric oxide synthase 
Fas ligand, perforin , granzyme and recently Granulysin) 
 
Apoptosis of keratinocytes 
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Histopathology 
Ranges from individual cell apoptosis to confluent epidermal necrosis, 
basal cell vacuolar degeneration and subepidermal vesicle or bulla formation, 
mild perivascular infiltrate of lymphocytes and histiocytes and eosinophils occur 
in the minority of cases[108] 
 
Image 3.9: Histopathology of SJS/TEN 
                  
 
Clinical features: 
 Occurs in all ages, but predominantly in children, infants and elderly with 
a female preponderance. Predominantly caused by drugs ,but a few cases 
especially in children caused by Mycoplasma pneumoniae[109]. Latency period  is 
typically 7–10 days, but  range from 5 to 28 days followed by a prodrome of 
malaise, fever and upper respiratory tract symptoms.  
                                            53 
 
Earliest skin lesions are atypical targets  and purpuric macules which  
commonly occur on the face, upper trunk and proximal limbs . Later spreads to 
involve entire body. Skin lesions increase over 5 - 7 days with development of 
vesicles and bullae. Nikolsky sign will be positive followed by epidermal 
detachment leading on to raw areas and secondary infection. 
 
Erosive and haemorrhagic mucositis of eyes, mouth, nose and genitalia is 
an early feature. Oral mucosal  involvement seen in 93%, eye involvement seen  
in 78% and genital mucosal  involvement in 63% [133]. All three sites were 
involved in 66%. Ocular lesions include chemosis, conjunctivitis, pseudo 
membrane, corneal and conjunctival epithelial defects. Oral manifestations 
include painful mucosal erythema with subsequent blistering and ulceration. 
Haemorrhagic crusts over vermilion of lips seen. Involvement of mucosa of 
oropharynx, larynx, respiratory tract and oesophagus seen in  severe cases. 
Urogenital tract involvement characterized by mucosal erythema, blistering and 
erosions.  
 
Pulmonary manifestations include dyspnoea, increased respiratory rate and 
bronchial hypersecretion. 
 
Severity of SJS/TEN[123] 
• SJS : epidermal detachment less than 10% BSA + widespread purpuric 
macules /flat atypical targets. 
• Overlap SJS -TEN: detachment of 10–30% BSA +  widespread purpuric 
macules/flat atypical targets. 
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• TEN with spots: detachment more than 30% BSA + widespread purpuric 
macules/ flat atypical targets. 
• TEN without spots: detachment more than 30% BSA +  loss of large 
epidermal sheets without purpuric macules/  target lesions 
 
Differential diagnosis: 
Erythema multiforme major, pemphigus vulgaris, mucous membrane 
pemphigoid, bullous pemphigoid, paraneoplastic pemphigus, bullous lupus 
erythematosus, linear IgA bullous dermatosis, generalized bullous fixed drug 
eruption, acute bullous acute graft – versus host disease, staphylococcal scalded 
skin syndrome, acute generalized exanthematous pustulosis. 
 
Complications:  
Acute: 
Hypothermia, transepidermal water loss, hyperglycaemia, 
hypoalbuminaemia, elevated liver enzymes, anaemia & neutropenia, acute kidney 
injury, hemoptysis, hypoxia, septiceamia (life threatening) 
 
Chronic: 
Skin  - Post inflammatory dyspigmentation, scarring, telogen effluvium, eruptive 
melanocytic naevi, abnormal sweating, photosensitivity, heterotopic ossification 
Ocular - corneal and conjunctival ulceration and scarring, dry eye, distichiasis, 
entropion, trichiasis, symblepharon or ankyloblepharon, ectropion and misdirected 
eyelashes. 
Oral mucosa - Gingival synechiae and sjogren like syndrome[124] 
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Lung - bronchiolitis obliterans[125] 
GIT -  Eosophageal stricture, diarrhea, malabsorption and vanishing bile duct 
syndrome 
Others  - vaginal and introital adhesions, psychological sequelae, including 
post‐traumatic stress disorder [126]. 
 
Disease course and prognosis: 
Skin lesions increases over first 5- 7 days , followed by re -epithelialisation 
and complete healing in 2-3 weeks with treatment. The overall mortality in 
SJS/TEN is about 22%; in SJS less than 10%, while in TEN the mortality is 
approximately 30% [127]. 
 
Prognosis: 
SCORTEN – (scores from 0-7) 
• Age greater than 40 years 
• Presence of malignancy 
• Heart rate >120 beats/min 
• Epidermal detachment >10% of BSA at admission 
• Serum urea >10 mmol/L 
• Serum glucose >14 mmol/L 
• Bicarbonate level <20 mmol/L 
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Table 3.4 : Mortality rate of SJS/TEN according to SCORTEN 
Number of parameters(%) Predicted mortality 
0 1.21 
1 3.2 
2 12.2 
3 32.4 
4 62.2 
5 85.0 
6 95.1 
7 98.5 
 
Investigations : 
Needed to substantiate  the diagnosis, exclude other blistering dermatoses 
and identify any systemic complications. 
Management: 
• Withdrawal of offending drug 
• Admission in intensive care unit 
• Temperature maintained at 25- 27 0 C 
Skin care: 
Greasy emollients, bath in a weak solution of chlorhexidine (1/5000), 
topical antibiotic in sloughed or crusted areas, silicon dressings, biological 
dressings and skin grafts. 
Care of mucosa:  
Eyes - Ocular lubricant must be applied 2nd hourly, broad spectrum topical 
antibiotic for corneal ulceration, amniotic membrane transplantation (AMT) for 
loss of ocular epithelia 
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Oral mucosa - Apply WSP ointment frequently to the lip, anti 
inflammatory oral rinse containing benzydamine hydrochloride every 3 hours and 
topical corticosteroid four times per day 
Urogenital mucosa - WSP ointment used as an emollient. Silicone sheet 
dressings for eroded areas in the vulva and vagina. Catheterisation to prevent 
urethral strictures 
Fluid replacement and nutrition:  
  Crystalloid fluid at 2 mL/kg body weight / % of BSA epidermal 
detachment. During catabolic phase 20–25 kcal/kg/day and anabolic phase 25–30 
kcal/kg/day  is needed[45]. 
Active therapy:  
• IVIG (0.5–1 g/kg daily for 3–4 consecutive days) 
• Systemic corticosteroid (e.g. prednisolone 0.5–1 mg/kg daily for 10 
days, and tapered; or IV methylprednisolone 500 mg on 3 
consecutive days) 
• Ciclosporin (3 or 4 mg/kg/day in divided doses for 10 days, and 
tapered) 
• Plasmapheresis 
• Single dose of TNF alpha inhibitor – Etanercept 
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Drug induced erythroderma: 
Characterised by erythema and scaling involving 90 % of BSA. Accounts 
for 2 – 8 % of all adverse cutaneous drug reactions and 5 – 40 %  of all 
erythroderma cases. 
Synonym: 
Drug induced exfoliative dermatitis 
Commonly implicated drugs: 
Antiepileptics, antibiotics, allopurinol, HAART, NSAIDs and 
complementary medicines. 
Pathogenesis: 
There is over expression of Th1 and Th2 type of cytokines and their 
ligands. Increased production of adhesion molecule CD61 by keratinocytes leads 
to hypersensitivity reaction by recruiting more epidermal T cells and Langerhan 
cells. 
Clinical features: 
Erythema, scaling and pruritis involving more than 90 % of BSA. Presence 
of constitutional symptoms such as fever and malaise along with 
lymphadenopathy, organomegaly and high output cardiac failure. 
Complications: 
Hypothermia, fluid and electrolyte imbalance, high output cardiac failure 
and sepsis. 
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Prognosis: 
Drug induced erythroderma has the best prognosis among all erythroderma 
cases and resolves in 6 – 8 weeks on withdrawal of offending drug. 
Treatment : 
Withdrawal of offending drug followed by emollients, topical and systemic 
steroids.   
 
Based on the above literature review, adverse cutaneous drug reactions are 
associated with significant morbidity and mortality especially in cases of SCAR. 
Among all the adverse cutaneous drug reactions, benign cutaneous drug reactions 
constitutes the majority ( >90%) and severe cutaneous adverse drug reactions 
(SCAR) constitute only 2 – 8 %. There is a slight female preponderance and 
majority of the reactions are seen in the elderly age group. 
Among the benign reactions maculopapular eruptions are the most 
common followed by urticaria, fixed drug eruptions, pruritis, acneiform eruptions 
with others constituting very less number of cases. Among the severe cutaneous 
drug reactions bullous lesions such as SJS/ TEN were the commonest, followed 
by erythroderma, DRESS and AGEP. 
Among the drugs commonly implicated in benign reactions, antibiotics, 
NSAIDs and antiepileptics constitute the majority with others being less common. 
Antileptics, antibiotics and allopurinol were the commonest drugs implicated in 
SCAR, with DRESS having a slightly different etiological profile compared to 
others. 
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 Presence of eosinophils was the consistent finding in HPE in majority of 
the cases, along with the findings in relation to the particular diagnosis.  
Majority of the benign reactions can be managed on a OP basis by 
withdrawal of the offending drug and with antihistaminics, emollients, topical and 
systemic steroids. SCAR needs admission in a ICU, early and appropriate 
management of complications to decrease the morbidity and mortality associated 
with them when compared to benign cutaneous drug reactions. 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
4.1 - Study design: 
 - Prospective observational study 
 
4.2 - Study centre: 
 - Department of Dermatology, Rajiv Gandhi Government General Hospital 
& Madras Medical College,  Chennai – 600 003. 
 
4.3 - Study period: 
 - November 2016 to September 2017 
 
4.4 - Study population: 
 - All patients who attended dermatology outpatient department with signs 
and symptoms of adverse cutaneous drug reactions are randomly selected for the 
study 
 
4.5 - Inclusion criteria: 
 - All patients aged more than 12 years presenting with skin and mucosal 
lesions following  exposure to a drug 
 
4.6 - Exclusion criteria: 
- Patients less than 12 years of age 
- Patients who were not willing to be included in the study 
- Patients who were not willing for follow up 
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4.7 - Sample size: 
 - All total of 36 patients who satisfied the above criteria were taken into the 
study. 
 
4.8 - Study approval: 
- Approval for the study was obtained from, Thesis & Ethical Committee 
of Madras Medical College and Rajiv Gandhi Government General Hospital, 
Chennai, prior to commencement of the study. 
 
4.9 - Methodology: 
 A clinico pathological study of adverse cutaneous drug reactions was 
carried out during the period of November 2016 to September 2017.  
 
Detailed case history was taken from each patient. Patients were enquired 
in reference to the duration and course of the disease, ailment for which the 
offending drug was taken, duration of treatment, route of administration, 
treatment taken for the present complaints, any previous history of similar 
complaints and any family history of cutaneous drug eruptions and were recorded. 
 
 In clinical examination, features like prodromal symptoms, site of 
involvement, morphology of  lesions like presence of maculopapular rash, target 
lesions, widespread erythema, erosions, peeling of skin and mucosal lesions were 
noted and complete dermatological examination was carried out. Nikolosky sign 
was elicited and Tzanck smear was done in patients with vesiculobullous lesions. 
Associated systemic symptoms were noted. 
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Routine investigations of all patients were performed which included a 
complete hemogram ,renal and liver function tests, VCTC, VDRL. In relevant 
cases USG abdomen, pus culture and sensitivity and scraping to rule out fungal 
infections was done. Skin biopsy from lesional skin was subjected to 
histopathological examination. 
 
All the parameters were recorded in a pretested proforma and were entered 
in a master chart, results were tabulated and analysed statistically. 
 
4.10 - Follow up procedures: 
Patients who were treated as out patients were asked to follow up after 4 
days. Patients who had extensive skin involvement and other systemic 
abnormalities were admitted and followed up.The investigation reports were 
collected, recorded and classified. The diagnosis was confirmed on the basis of 
clinical, biochemical and histopathological features. Patients were treated 
according to their relevant diagnosis. 
 
4.11- Ethical Issues 
Participants were made aware about the nature and purpose of the study. It 
was also informed to all the participants that all data provided by the patients will 
be kept confidential and will be used only for the study purpose. Willingness and 
signature of the participants were taken on a previously designed consent form. 
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Written consents were obtained from all the subjects who participated in 
the study before data collection. Detailed description of the study and the aspects 
of patient confidentiality are explained to the subject and voluntary participation 
is sought. Institutional ethics committee of Madras medical college reviewed the 
study proposal for ethical consideration and approval. 
   
  
Observations & Results 
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OBSERVATION AND RESULTS 
 
 Total number of patients who attended our OPD during the study period 
and satisfied the criteria for the study was 36. Total number of new cases in our 
OPD during the study period ( November 2016 to September 2017 ) was 37948. 
Hence the incidence of adverse cutaneous drug reactions in our study population 
was 0.949 per 1000 person years (patients above 12 yrs of age). 
    
Table 5.1 : Incidence rate of adverse cutaneous drug reactions in our OPD 
No. of new cases 
(1 year) 
(above 12 yrs of age) 
No. of study patients 
(above 12 yrs of age) 
Incidence 
(above 12 yrs of age) 
 
41398 
39.27 ( calculated for 1 
year with the incidence in 
previous 11 months) 
0.949 per 1000 person 
years 
 
 Table 5.2 shows the mean age group of  our study population which was  
39.33 (± 20.13, range 13 – 75 years). The lowest age in our study group was 13 
years  and the highest being 75 years.  
  
                                            66 
 
Table 5.2: Age distribution 
Age group( in years) No. of patients Percentage 
12 - 20 8 22 
21 -30 8 22 
31 – 40 4 11 
41 – 50 3 9 
51 – 60 4 11 
61 – 70 8 22 
71 - 80 1 3 
 
Chart 5.1: Graphical representation of age distribution 
 
 Table 5.3 shows the sex distribution among the study group, with 20 (56%) 
patients being males and 16 (44%) patients being females. Male to female ratio 
was 1.25: 1.    
12 - 20 years
22%
21 - 30
22%
31 - 40
11%
41 - 50
9%
51 - 60
11%
61 - 70
22%
71 - 80
3%
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Table 5.3: Sex distribution 
Sex No. of patients Percentage 
Males 20 56 
Females 16 44 
      
   Chart 5.2: Graphical representation of  sex distribution  
 
 
 Out of the 36 patients in our study, one female who presented with 
generalized bullous FDE, had a family history of FDE (H/o of  FDE in her father, 
but drug details were not available ). None of the other study patients had any 
family history of drug hypersensitivity reactions.  
 
 Of the total 36 patients , 25 (69%) patients had benign cutaneous drug 
reactions and 11(31%) patients had severe cutaneous drug reactions, as shown in 
table 5.4 
Males 
56%
Females
44%
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Table 5.4: Type of drug reactions 
Type of reaction No . of patients Percentage 
Benign 25 69 
Severe 11 31 
 
    Chart 5.3: Graphical representation of type of drug reaction  
  
 
Among the various clinical presentation, fixed drug eruption (FDE) was 
the commonest seen in 10 (28%) patients, followed by maculopapular rash 
(exanthem) in 8 (22%) of patients, SJS/ TEN in 7 (19%) patients, acneiform 
eruptions in 4 (11%), erythroderma in 2 (6%), EMF in 2 (5%), lichenoid 
reation,DRESS and SJS/DRESS overlap in 1 patient each, as shown in table 5.5. 
  
Benign
69%
Severe
31%
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Table 5.5: Clinical presentation 
Diagnosis No. Of Patients Percentage 
Acneiform eruptions 4 11 
DRESS 1 3 
EMF 2 5 
Erythroderma 2 6 
Exanthem 8 22 
FDE 10 28 
Lichenoid reaction 1 3 
SJS/DRESS 1 3 
SJS/TEN 7 19 
         
        Chart 5.4 – Graphical representation of various clinical presentation   
     
Table 5.6 shows the various symptoms associated with adverse cutaneous 
drug reactions, with itching being the most common, seen in 23(64% )patients, 
followed by burning sensation/ pain seen in 8(22% )patients, scaling in 6(17% ) 
patients and facial puffiness in 4(11% ) patient. 8 (22% ) patients didn’t have any 
associated symptoms. 
Acneiform 
eruptions
11%
DRESS
3% EMF
5%
Erythroderma
6%
Exanthem
22%FDE
28%
Lichenoid 
reaction
3%
SJS/DRESS
3%
SJS/TEN
19%
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Table 5.6 : Associated symptoms 
Associated symptoms No. of  patients Percentage 
Burning  sensation/Pain 8 22 
Itching 23 64 
No associated symptoms 8 22 
Puffiness of face 4 11 
Scaling 6 17 
   
      Chart 5.5: Graphical representation of associated symptoms 
 
 
The most common offending drug in our study was NSAIDs (33% ), 
followed by antiepileptics (25% ), antibiotics (19% ), systemic steroids (5% ), 
chemotherapeutic agent ( 3%) and topical steroid (3% ). The causative drug was 
unidentifiable in 2 (6% ) patients as and was unknown in 3 (8% ) patients. Details 
were shown in table 5.7 
  
Burning  sensation/Pain
Itching
No associated symptoms
Puffiness of face
Scaling
8
23
8
4
6
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Table 5.7: Causative drug in adverse cutaneous drug reaction in our study 
Offending Drug No of Patients Percentage 
Antimicrobials 6 17 
Antiepileptics 9 25 
Chemotherapeutic agents 1 3 
NSAIDs 12 33 
Topical steroids 1 3 
Systemic steroids 2 5 
Unknown 3 8 
Unidentifiable 2 6 
 
Chart 5.6: Graphical representation of causative drug 
    
Out of the 36 patients in our study, 29 patients had taken drugs prescribed 
by a physician and 7 patients had taken over the counter drugs, as shown in table 
5.8 
Antimicrobials
17%
Antiepileptics
25%
Chemotherape
utic agents
3%
NSAIDs 
33%
Topical 
steroids
3%
Systemic 
steroids
5%
Unknown
8%
Unidentifiable
6%
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    Table 5.8: Prescription status of causative drug 
Prescription status No. of  patients Percentage 
Physician prescribed 29 81 
Over the counter 7 19 
 
 Body surface area involvement ( BSA ) of skin lesions among our study 
patients is shown in table 5.9 
                     Table 5.9 : Body surface area involvement 
BSA No. of patients Percentage 
< 10% 8 22 
10 - 30 % 12 34 
31 - 90 % 13 36 
>  90 % 3 8 
 
Chart 5.7 : Graphical representation of body surface area involvement 
    
Comorbidities seen in patients with adverse cutaneous drug reactions in our 
study is shown in table 5.10 
< 10%
22%
10 - 30 %
34%
31 - 90 %
36%
>  90 %
8%
BSA involvement
                                            73 
 
  Table 5.10: Associated co morbidities 
Co morbidities No of Patients Percentage 
CVS 2 5 
Dermatological 1 3 
Diabetes Mellitus 2 5 
Malignancies 2 5 
CNS 6 16 
No co-morbidities 17 45 
RS 2 5 
OA Knee 2 5 
SHT 4 11 
 
             Chart 5.8: Graphical representation of  associated co morbidities 
     
The erythrocyte sedimentation rate (ESR) values in our study patients is 
shown in table 5.11.  27 (75 %) patients had raised ESR. 
  
CVS
5%
Dermatological Diabetes 
Mellitus
5%
Malignancies
5%
CNS
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No co-
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Table 5.11: Erythrocyte sedimentation rate (ESR) 
ESR No.of patients Percentage 
Normal 9 25 
Raised 27 75 
  
Chart 5.9: Graphical representation of ESR 
 
 
In our study population, 19 (53%) out of 36 patients had elevated absolute 
eosinophil count. 9 (82%) out of 11 patients with severe adverse cutaneous drug 
reactions and 10 (37%) out of 27 patients with benign cutaneous drug reactions 
had elevated eosinophil counts, which is shown in table 5.12. 
  
Normal
Raised
9
27
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     Table 5.12: Absolute eosinophil count in our study patients 
 
Chart 5.10 : Graphical representation of absolute eosinophil count in  
our  study patients  
      
0 2 4 6 8 10
Acneiform eruptions
DRESS
EMF
Erythroderma
Exanthem
FDE
Lichenoid reaction
SJS/DRESS
SJS/TEN
Total cases Cases with AEC > 440
Clinical presentation No. of patients with AEC > 440 Percentage 
Acneiform eruptions (n=4) 1 25 
DRESS (n=1) 1 100 
EMF (n=2) 0 0 
Erythroderma (n=2) 2 100 
Exanthem (n=8) 4 50 
FDE (n=10) 5 50 
Lichenoid reaction (n=1) 0 0 
SJS/DRESS (n=1) 1 100 
SJS/TEN (n=7) 5 71 
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In our study population, only 11 patients had elevated biochemical 
parameters at the first visit for OP patients and at the time of admission for 
patients with SCAR. 6 (54% ) out of 11 patients with SCAR had elevated 
biochemical parameters and only 5 (20% ) patients out of 25 with benign adverse 
cutaneous drug reactions had elevated biochemical parameters. The details have 
been tabulated (Table 5.13) 
 
       Table 5.13: Biochemical parameters in our study patients 
CLINICAL 
PRESENTATION 
 
↑SGO
T 
 
↑SGPT 
↑AL
P 
↓SERUM 
ALBUMI
N 
↑RB
S 
↑URE
A 
Acneiform eruptions 
(n=4) 0 0 0 1 1 0 
DRESS (n=1) 1 1 1 1 0 1 
EMF (n=2) 0 0 0 0 0 0 
Erythroderma (n=2) 1 1 1 1 0 0 
Exanthem (n=8) 1 0 0 0 1 0 
FDE (n=10) 2 2 2 1 0 0 
Lichenoid reaction (n=1) 0 1 0 0 0 1 
SJS/DRESS (n=1) 0 0 0 0 0 0 
SJS/TEN (n=7) 4 4 2 3 1 3 
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Chart 5.11 : Graphical representation of biochemical parameters in our 
study patients 
 
The histopathological features of various clinical presentation of adverse 
cutaneous drug reactions has been recorded and tabulated. The commonest 
presentation was the presence of dermal perivascular and interstitial lymphocytic 
infiltrate along with presence of eosinophils in most of the cases and neutrophils 
in few cases. Hyperkeratosis and follicular plugging was seen in acneiform 
eruptions. Spongiosis, basal cell degeneration and necrotic keratinocytes were 
commonly seen in FDE and SJS / TEN. Pigment incontinence and dermal 
melanophages were seen in cases of FDE. Subepidermal split and bullae were 
seen in SJS / TEN and bullous FDE cases. Band like upper dermal inflammatory 
infiltrate was seen in a case of lichenoid drug reaction. Various histopathological 
features are shown in table 5.13 and its graphical representation in chart 5.11. 
 
0 1 2 3 4 5 6 7 8 9
↑  SGOT
↑  SGPT
↑  ALP
↓  Sr.ALBUMIN
↑  RBS
↑  UREA
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Table 5.14 : Histopathological features in our study population 
 
 
 
Clinical presentation 
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Acneiform eruptions  
( n - 4 ) 4 0 2 0 1 0 0 0 0 0 
DRESS ( n - 1 ) 1 0 0 1 1 1 0 1 0 0 
EMF ( n - 2 ) 0 0 0 2 2 0 0 2 0 0 
Erythroderma 
( n - 2 ) 2 1 0 2 0 0 0 1 0 0 
Exanthem 
( n - 8 ) 2 0 0 7 2 0 0 3 0 0 
FDE ( n - 10 ) 4 0 0 8 4 10 6 3 10 10 
Lichenoid reaction  
( n - 1 ) 1 1 0 1 1 1 0 0 1 1 
SJS/DRESS 
( n - 1 ) 0 0 0 1 1 1 1 1 0 0 
SJS/TEN ( n - 7 ) 2 0 0 7 7 7 6 6 1 0 
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Chart 5.12 : Graphical representation of histopathological features in our 
study population 
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Clinical Images 
  
IMAGE 1 
 
 
Fixed drug eruption (FDE) 
 
 
 
 
 
 
 
 
  
 
Histopathology of FDE shows spongiosis (green arrow),  
lymphocytic infiltrate (yellow arrows) and pigment incontinence  
and melanophages in dermis (blue arrow). 
 
  
IMAGE 2 
 
 
Generalised bullous fixed drug eruption (GBFDE) 
 
 
 
 
 
 
 
 
  
 
Multiple erythematous and hyperpigmented patches  
and plaques with bullae 
 
  
IMAGE 3 
 
 
Drug induced exanthem 
 
 
 
 
 
 
 
 
  
 
Histopathology of drug induced exanthem shows spongiosis ( yellow arrow )  
and perivascular lymphocytic infiltrate ( green arrow ) 
 
  
IMAGE 4 
 
 
Steven Johnson syndrome 
(Epidermal detachment <10% BSA) 
 
 
 
 
 
 
 
  
 
Histopathology of SJS shows -  spongiosis & basal cell degeneration (blue arrow), 
necrotic keratinocytes (green arrow) and lymphocytic infiltrate (yellow arrow). 
 
IMAGE 5 
 
 
Toxic epidermal Necrolysis (TEN) 
 
 
 
 
 
 
 
  
 
Epidermal detachment involving >30 % BSA & mucosal involvement 
 
  
IMAGE 6 
 
 
     Drug induced lichenoid eruption 
 
 
  
  
 
 
 
 
HPE of the lesions show – parakeratosis (orange arrow), spongiosis (black arrow), 
basal cell degeneration (green arrow), colloid bodies (blue arrow) & band like 
inflammatory infiltrate in the upper dermis (yellow arrows) 
 
IMAGE 7 
 
 
Erythroderma 
 
 
 
 
 
 
 
 
 
 
 
 
  
IMAGE 8 
 
 
Erythema multiforme 
 
 
 
 
 
 
 
 
 
HPE of the lesion shows – basal cell degeneration (green arrow), necrotic 
keratinocytes (black arrow), subepidermal split (red arrow) in cases of bullous 
emf & perivascular infiltrate (yellow arrows). 
 
 
 
Discussion 
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DISCUSSION 
 Adverse cutaneous drug reactions ( ACDR ) are one of the underestimated 
causes of significant morbidity in both hospitalized and outpatients. In patients 
with severe cutaneous adverse drug reactions , the mortality is high if not 
diagnosed early and managed appropriately. Various studies had been conducted 
over the years to assess the incidence, various clinical presentations and common 
offending drugs. 
 
 The incidence of adverse cutaneous drug reactions in our study population 
was 0.949 per 1000 person years in patients above 12 years of age. In a study 
conducted by Chatterjee et al , the incidence of adverse cutaneous drug reactions 
was found to be 2.6 per 1000 in a dermatology outpatient clinic[128]. In another 
study conducted by Abanti S  et al , the primary incidence of ACDR in a 
dermatology outpatient setting was found to be 2.05 per 1000[39]. The decreased 
incidence seen in our study can be attributed to the fact that most of the patients 
with milder forms of drug reactions do not report to us, and are treated in private 
clinics around our study centre. 
 
 The mean age of our study population was 39.33( ± 20.33, 13 – 75 years ). 
This is in concordance with the studies conducted by Pudukadan et al and  Abanti 
S et al , where the mean age has been 37.06 ( ± 30.12, 9 – 75 years) and 33.8 (± 
17.19, 4 – 82 years ) respectively[37,39] . 55 % of our patients were in the age group 
of 12 – 40 years, which was in concordance to the studies conducted by 
Pudukadan et al , Abanti S et al and Patel Raksha M et al where 47 / 90 patients 
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were in the age group of 20 – 39 years, 52.80% of patients in the 16 – 35 years 
age group  and 52% in the 11 – 40 years group respectively[37,39,129]. 
 
 Among our study population, 20 were males and 16 were females with a 
ratio of  1.25 : 1. According to Pudukadan et al the male to female was 0.87 : 1 
and it was 1.04 : 1 in a study conducted by Anjaneyan G  et al[129,130]. In the 
studies conducted by Abanti S et al and Patel Raksha M et al, the male to female 
ratio had been 0.95 : 1 and 1.27 : 1 respectively. The male to female ratio in our 
study is in concordance with the study conducted by Patel Raksha M et al but the 
slight difference from other studies can be attributed to the geographical 
variations in the study population. 
 
Table 7.1 : Male to female ratio in adverse cutaneous drug reaction 
Study Male to female ratio 
Pudukadan et al ( 2001 – 03) 0.87 : 1 
Patel Raksha M et al (1997 – 2006 ) 1.27 : 1 
Abanti S et al ( 2008 – 09 ) 0.95 : 1 
Anjaneyan G  et al ( 2010 – 11) 1.04 : 1 
Our study 1.25 : 1 
 
The commonest clinical presentation in our study  was fixed drug eruption  
( FDE) seen in 10/36 patients, followed by maculopapular rash in 8/36, SJS/TEN 
in 7/36, acneiform eruptions in 4/36, erythema multiforme & erythroderma in 2 
patints each and lichenoid drug eruption, DRESS and SJS/DRESS overlap in 1 
patient each. The percentage of various drug eruptions in studies conducted by 
Pudukadan et al, Abanti S et al, Anjaneyan et al, Patel Raksha M et al and 
                                            82 
 
Luciane et al has been compared in table 6.2[131]. The various clinical presentation 
of adverse cutaneous drug reactions in our study is in concordance with the study 
conducted by Pudukadan et al and Abanti S et al.  
 
         Table 7.2 : Percentage of various drug eruptions in other studies 
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Pudukadan et al 31.1 12.2 18.8 6.7 3.3 3.3 4.4 - 
Abanti S et al 24.5 30.18 24.5 - - 7.54 - - 
Anjaneyan G et al 23 25 4 1 10 - - 2 
Patel raksha M et al 30.5 18 4 1 2.5 2.5 - - 
Luciane F F Botelho 
et al - 37.6 12.8 - - - - 14.5 
Our study 28 22 19 6 11 6 3 3 
 
One patient out of the 36, presented with generalized bullous FDE, and 
gave history of drug hypersensitivity reaction in the family. Her father had FDE 
but details were not available regarding the offending drug . There was no such 
report of occurrence of same type of drug eruption in the family on reviewing the 
previous studies. 
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 In our study the commonest drugs causing  adverse cutaneous reactions 
were NSAIDs ( 33% ) followed by anticonvulsants ( 25% ) and antibiotics (19% ). 
The causative agent was unidentifiable in 5% of patients as they were under 
multiple medications and unknown in 9% of patients, as they have had over the 
counter medications and were unaware of the drug details. In Pudukadan et al 
study cotrimoxazole ( 22.2% ) was the commonest offending drug, followed by 
dapsone ( 17.8% ), anticonvulsants ( 14.5%) and NSAIDs ( 12.1% ). In the study 
by Abanti S et al antibiotics constituted 50.9% , followed by anticonvulsants and 
NSAIDs each constituting 11.3 % [37,39]. In the study conducted by Luciane F F 
Botelho et al, 23.9 % of the reactions were due to anticonvulsants, 22.2% due to 
antibiotics  and 29 % patients were taking multiple medications[131]. 
 
Severe cutaneous drug reactions in our study were caused most commonly 
by antiepileptics ( 55% ), followed by antibiotics and NSAIDs each constituting 
18%.  Antibiotics ( 59% ) were the commonest cause, followed by anticonvulsants 
(26% ) and NSAIDs (3.8%) for SCAR in Pudukadan et al study. The slight 
discordance in the causative agents between the studies can be attributed to the 
small sample size in our study. 
 
Out of the 36 patients in our study, 29 (81%) patients had developed 
reactions to physician prescribed drugs and 7 ( 19% ) patients due to over the 
counter ( OTC ) medications. This is in concordance with the study by Abanti S et 
al where physician prescribed drugs constituted 88.7 % and OTC drugs 11.3%. 
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Cutaneous drug reactions due to OTC drugs constitutes a significant proportion 
and steps should be taken to prevent patients going for OTC medications by 
proper counselling of patients and strict rules to be laid down for pharmacies 
regarding drug distribution. 
 
Table 7.3 : Commonly incriminated drugs in drug eruptions 
Study Anticonvulsants Antibiotics NSAIDs Multiple drugs 
Pudukadan et al 14.5% 41% 12.1% - 
Abanti S et al 11.3% 50.9% 11.3% - 
Luciane F F 
Botelho et al 23.9% 22.2% - 29% 
Our study 25% 19% 33% 5% 
  
 Most common presenting symptom was itching  ( 64% ), followed by skin 
rashes ( 61% ), burning sensation & pain in the skin  ( 22.2% ) and fluid filled 
lesions (16.7% ). This is in concordance with the study conducted by Anjaneyan 
et al where itching (37% ) was the commonest presentation, followed by rash ( 
18% ) and swelling (15% ).  
 
 Mean latency period in our study population was 17.90 ± 46.06  days                      
( range, 1 –  180 days ),  in which 2 patients with acneiform eruptions, 1 with 
exanthem and 1 patient with lichenoid eruption had a latency period ranging from 
4 months to 6 months and patients with FDE had the shortest latency of 4 hours . 
This is in concordance with Pudukadan et al study in which the mean latency 
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period was 14.01 days  ( 1 – 172 days ), but with a slight difference from the study 
by Abanti S et al where the mean latency period was 6.2 days ( 1 – 43 days )[37,39]. 
 
Table 7.4 :Mean latency period between drug intake and onset of drug   
eruption 
Study Mean latency period ( in days ) 
Range 
( in days ) 
Pudukadan et al 14.01 1 - 172 
Abanti S et al 6.2 1 - 43 
Our study 17.90 1 - 180 
 
 Among the co morbidities associated with drug reactions, CNS disorders     
( 16.6 ) was the commonest, followed by SHT ( 11%), diabetes, CVS disorders, 
RS disorders, malignancies & OA knee each constituting 5%. No associated co 
morbidities was seen in 47% of the patients. This is concordance with the study 
conducted by Pudukadan et al  where a previous systemic illness was present in 
48.09% of patients. 
 
 Skin lesions were involving  < 10% body surface area (BSA) in 22% , 10 – 
30 %  BSA in 34%, 31 – 90 % BSA in 36% and >90 % BSA in 8% of patients in 
our study.  In Pudukadan et al study  46% , 16%, 34% and 4% patients have had   
< 10%, 10 – 30 %, 31- 90 % and > 90 % BSA involvement respectively. In 
Anjaneyan et al study 38 %, 44% and 18% of patients have had 0 -25%, 26 – 75 
% and > 76 % BSA respectively . The results of BSA involvement of skin lesions 
in our study is in concordance with other studies. 
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Table 7.5 : Body surface area involvement ( BSA ) 
Study <  10 % 10– 30 % 31– 90 % > 90% 
Pudukadan et al 46% 16% 34% 4% 
Our study 22% 34% 36% 8% 
 
 Regarding absolute eosinophil counts ( AEC ), among our study patients 
19/36 ( 53% ) patients  had  high AEC ( >440 cells/cumm).  9/11 ( 82% ) patients 
with SCAR had AEC > 440, which was statistically significant . 8/11 (73%) 
patients with SCAR had AEC > 1000, with highest AEC of 2960 was seen in a 
patient with DRESS. This is in concordance to Pudukadan et al study where 42.2 
% of patients had AEC > 500, and the study by Anjaneyan et al in which 15 % of 
patients had high AEC and 3/7 patients with SCAR have had AEC > 500.  
According to American Academy of Dermatology, a high eosinophil count of  
more than 1000 cells / cumm indicates severe cutaneous drug reactions[132]. In a 
study by Ramagosa et al , high eosinophil counts was found to have little 
diagnostic value in adverse cutaneous drug reations[133]. Though high AEC is of 
little diagnostic value it might have a prognostic significance in SCAR and further 
studies are needed to validate it. 
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Table 7.6 : Absolute eosinophil count (AEC) 
Study AEC > 440 in total study patients 
In Benign 
reactions 
In Severe 
reactions 
Pudukadan et al 42.2% - - 
Anjaneyan et al 15% - 43% 
Our study 53% 40% 82% 
 
 Elevated liver parameters like raised SGOT, SGPT and ALP was seen in 
25 % of our study patients mostly in those with severe cutaneous drug reactions, 
and abnormalities in other biochemical parameters were seen in 19 % of patients. 
23.3% of patients have had liver function abnormalities and 10 % have had other 
abnormal biochemical values in the study by Pudukadan et al. The results of our 
study is in concordance with the previous studies. 
 
Table 7.7 : Abnormalities in biochemical parameters in study patients 
Study Elevated liver enzymes Abnormality in other biochemical parameters 
Pudukadan et al 23.3% 10% 
Our study 25% 19% 
 
 By histopathological examination ( HPE ) the most common observed 
feature in our patients was  dermal lymphoytic infiltrate, followed by spongiosis, 
necrotic keratinocytes, basal cell degeneration and dermal edema. Pigment 
incontinence and melanophages was predominantly seen in cases of FDE. 
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Eosinophils in the dermal infiltrate was seen in most of the cases except for cases 
of acneiform eruptions where neutrophils predominated along with 
lymphocytesand follicular plugging.  Basal cell degeneration, necrotic 
keratinocytes, subepidermal bulla and lymphoytic infiltrate were the common 
HPE findings in cases of DRESS, SJS, TEN and bullous FDE. In a study by 
Weinborn M et al, spongiosis, dermal edema, basal cell degeneration, 
lymphocytic infiltrate and rare necrotic keratinocytes were seen in cases of 
DRESS and necrotic keratinocytes were absent in cases of maculopapular 
rash[134]. In our study necrotic keratinocytes were seen in 2 out of 8 cases of 
maculopapular rash and in all the cases of  bullous FDE, SJS, TEN and DRESS. 
HPE is not a specific diagnostic modality in cases of drug reactions and there 
were not much studies conducted comparing the various histopathological featurs 
in drug reactions. But it would be helpful in cases where the diagnosis is in doubt, 
such as maculopapular rash and DRESS. 
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Table 7.8 : Histopathological features of various clinical presentation  of 
ACDR in our study patients 
Clinical 
presentation Commonest HPE features seen in our study 
Acneiform 
eruptions  
Hyperkeratosis, follicular plugging, follicular & 
perifollicular lymphocytic and neutrophilic infiltrate 
DRESS  Spongiosis, necrotic keratinocytes, basal cell degeneration, perivascular lymphocytic infiltrate 
EMF  Spongiosis, necrotic keratinocytes, perivascular and interstitial eosinophilic  & lymphocytic infiltrate 
Erythroderma  
Flaky hyperkeratosis, spongiosis, dermal edema, 
perivascular and interstitial neutrophilic & lymphocytic 
infiltrate 
Exanthem  Hyperkeratosis, spongiosis, perivascular lymphocytic infiltrate with eosinophils & rarely necrotic keratinocytes 
FDE  
Spongiosis, necrotic keratinocytes, basal cell degeneration, 
perivascular and interstitial lymphocytic infiltrate, pigment 
incontinence and dermal melanophages 
Lichenoid reaction  
Hyperkeratosis, basal cell degeneration, few colloid bodies 
and eosinophils, band like upper dermal inflammatory 
infiltrate. 
SJS/TEN  
Spongiosis, necrotic keratinocytes, basal cell degeneration, 
sub epidermal bulla,  perivascular and interstitial 
lymphocytic & eosinophilic infiltrate 
 
  
Limitations of the Study 
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LIMITATIONS OF THE STUDY 
 
1. Sample size in our study was small. Only 36 patients presented to our 
department during the study period. 
2. Children less than 12 years present initially to Institute of child health 
(ICH), Egmore, Chennai. Patients are sent here for opinion, but further 
follow up is not available and hence we were not able to include them in 
the study.  
3. Milder form of adverse cutaneous drug reactions mimics some of the 
common dermatoses and are misdiagnosed and treated as dermatological 
disorders in private clinics and those patients don’t present to us. 
4. Specific investigations to diagnose the causative drug in cases where the 
patient is on polypharmacy are not available, apart from oral challenge test 
which pose a significant risk to the patients.   
5. Histopathological examination of lesional skin which is diagnostic in most 
of the dermatological disorders doesn’t have a high predictive value in 
cases of adverse cutaneous drug reactions. 
 
  
Conclusion 
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CONCLUSION 
 
 In a clinico pathological study of adverse cutaneous drug reactions 
conducted in our Department of Dermatology, Rajiv Gandhi Government General 
Hospital and Madras Medical College, Chennai during the period of  November 
2016 to September 2017, in a total of 36 patients, 
 
1. Males were more commonly affected than females in a ratio of 1.25:1. 
2. Mean age group of the study population was 39.33 years, with majority of 
patients in the 2nd, 3rd and 7th decade. 
3. Itching was the most common presenting complaint (64%), followed by 
burning sensation and scaling. 
4. 69%  of patients presented with benign drug eruptions and 31% of patients 
presented with severe cutaneous adverse reactions.   
5. Fixed drug eruption (FDE) was the commonest benign cutaneous adverse 
reaction, seen in 28% of the patients. 
6. Non steroidal anti inflammatory drugs (NSAIDs) (33%) were the most 
common offending drug followed by anticonvulsants (25%) and antibiotics 
(17%). 
7. Steven Johnson syndrome / Toxic epidermal necrolysis ( SJS/TEN) was the 
most common severe cutaneous adverse drug reaction (19% ) and 
anticonvulsants were the commonest cause of  severe cutaneous adverse 
drug reactions (63.5%). 
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8. Elevated absolute eosinophil count of  more than 1000 cells / mm³ was 
seen in 82% of patients with severe cutaneous drug reactions on admission. 
9. Abnormalities in biochemical parameters were seen predominantly in 
patients with severe cutaneous adverse drug reactions (SCAR), with 
elevated liver enzymes (30.5%) being the most common abnormality. 
10.  On histopathological examination of skin lesions, spongiosis and presence 
of few necrotic keratinocytes were the commonest finding, with basal cell 
degeneration and extensive keratinocyte necrosis being seen mostly in 
patients with severe cutaneous adverse drug reactions. 
11.  One female patient in our study presented with history of similar drug 
reaction in her family. 
 
Adverse cutaneous drug reactions are a cause of significant morbidity and 
mortality in cases of SCAR, in both outpatients and hospitalized patients. 
Anticonvulsants are the commonest offending drugs in severe cutaneous drug 
reactions. Hence the treating physician should obtain a detailed history regarding 
previous drug reactions, exercise caution in prescribing such medications and 
should have high index of suspicion to diagnose these cases early which may be 
life saving to the patient.  
 
High absolute eosinophil count may have prognostic significance in cases 
of severe cutaneous drug reactions , though it not diagnostic of such an event. 
Significant number of patients with cutaneous drug reactions, especially those 
with severe reactions have elevated liver enzymes and abnormalities in other 
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biochemical parameters, the nature of which will be helpful in assessing the 
severity of the disease.  
 
Histopathological examination of skin, though it doesn’t show  any specific 
feature pertaining to any of the drug reaction, will be helpful in differentiating 
cases of drug reaction from other dermatoses which has features similar to drug 
reaction, and are difficult to diagnose by clinical examination alone.  
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Annexures 
ABBREVIATIONS 
 
ACDR  – Adverse cutaneous drug reaction 
ADR   – Adverse drug reaction 
AGEP  – Acute generalized exanthematous pustulosis 
AIDS   – Aquired immune deficiency syndrome 
ANA   – Anti nuclear antibodies 
DIF   – Direct immunofluoroscence 
DRESS  – Drug reaction with eosinophilia and systemic symptoms 
EGFR  – Epidermal growth factor receptor 
FDA   – Food and drug administration 
FDE   – Fixed drug eruption 
GBFDE  – Generalised bullous fixed drug eruption 
GMCSF  – Granulocyte monocyte colony stimulating factor 
HLA   – Human leucocyte antigen 
ICAM  – Intercellular adhesion molecule 
IPC   – Indian pharmacopoeia commission 
LE   – Lupus erythematosus 
MHC   – Major histocompatibility complex 
NCC   – National co ordination centre 
NSAIDS  – Non steroidal anti inflammatory drugs 
PCR   – Polymerase chain reaction 
PvPI   – Pharmaco vigilance programme of India 
RAST  – Radio allergosorbent assay 
SDRIFE  – Symmetrical drug related intertriginous and flexural  
exanthem 
SJS/TEN  – Steven Johnson syndrome / Toxic epidermal necrolysis 
SSLI   – Serum sickness like illness 
TCR   – T cell receptor 
TLR   – Toll like receptor 
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30 P30 27 M Y N N Y N N Y N N 5 N N N Y N N N Y N N N N N N N N N 100 100/66 100 Y N Y Y Y 10 Y N Y n n P 13.4 14 59,22,19 1.22 50 1420 n n Ad SJS Cotrimoxazole
31 P31 20 M Y N N N Y N N N N 120 N N N N N Y N N N N N Y N N Y N N 78 110/79 n Y N N N N 20 N N N n n n 10 5 69,16,15 1.9 24 760 Mi,H n Ad Acne . Erup CTP  drug/Steroids
32 P32 66 F N Y Y N N N N N N 0.5 N Y N N N N N N N N N Y N N N N Y 89 146/96 100 Y Y N N Y <10 Y N N n n
H
A
9.2 9.3 85,7,8 0.84 36 550 Mi,H n D Bullous FDE Unknown
33 P33 61 M Y N N N N N Y Y N 30 N N N N N N N N N Y N Y N N N N Y 110 90/60 102 Y N Y N Y 50 Y N Y n n P 8.8 18 74,18,8 2.47 48 1192 Mi,H Eo Ad TEN Phenytoin
34 P34 68 F N Y Y Y N N N N N 0.3 Y Y N N N N N N N N N N N N N N N 85 136/70 n N Y N N Y 10 N N N n n n 13.4 11 62,30,8 4.75 42 879 n n Ad Bullous FDE NSAID
35 P35 65 F Y N N Y Y Y N N N 2 N N N N N N N N N N Y N N N N N 96 120/70 n Y N N N N 90 N N N n n S 8.3 13 66,26,8 3.67 31 1024 Mi,H n Ad Exanthem Paracetamol
36 P36 14 M Y N N Y N N Y Y N 14 N N N N N N N N N N N Y N N N N N 100 80/50 100 Y N Y N Y
20-
30
Y N Y n n P 8.8 5.5 70,26,4 3.56 30 310 Mi,H n Ad SJS/TEN Carbamazepine
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1 P1 55 F T Nil 142 1 0.1 17 22 94 6.4 3.8 31 0.7 130 35 Ne NR n N N Y Y N N PV,INT L,E N N N N Exanthem NSAID
2 P2 17 M Nil Nil 74 0.9 0.3 42 31 179 7 4 21 0.6 135 5 Ne NR n N N Y N Y N PV,INT L,E N Y N N EMF Phenytoin
3 P3 29 F Nil Nil 116 0.6 0.1 21 19 87 6.2 4 29 0.7 139 4.6 Ne NR n Y N N N Y N F ,PF N,L N N N N Acne . Erup OCP
4 P4 50 F Nil Nil 172 1 0.4 39 42 112 6.4 4.2 40 0.9 136 3.9 Ne NR FL Y Y Y N N ` BL L,E N N Y Y Liche. Derm Thiazides
5 P5 40 M T Nil 89 0.6 0.1 18 31 123 6.9 3.7 15 0.7 129 3.4 Ne NR n N N Y Y N N PV,INT L,E N N N N Exanthem CTP  drug/Phenytoin
6 P6 65 M Nil Nil 131 1 0.4 27 22 89 6.4 3.8 42 1.2 135 3.5 Ne NR n N N Y N Y Y BL L,E Y N Y Y Bullous FDE NSAID
7 P7 21 M Nil Nil 107 0.8 0.5 38 40 151 5.4 3.1 18 0.8 137 3.8 96 Ne NR n N N Y N N Y PV,PA L,PC,E Y Y N N DRESS/SJS NSAID
8 P8 14 F Nil Nil 120 1.2 0.4 40 38 194 6 3.6 30 0.7 132 4.6 Ne NR n N N Y N Y Y PV,INT L,E Y N Y Y GBFDE NSAID
9 P9 18 F T Nil 91 0.5 0.3 66 73 67 6.4 3.3 37 1.2 130 3.3 100 Ne NR n N N Y N Y Y PV,INT L,E Y N Y N SJS Carbamazepine
10 P1 61 F Nil Nil 90 0.2 0.12 22 26 145 7.9 4 18 0.8 142 4.8 Ne NR n Y N Y N N N PV,INT L,E N Y N N Erythroderma Cephalosporin/NSAID
11 P11 70 M Nil Nil 78 0.9 0.3 17 21 58 5.6 3 52 0.9 134 4.2 96 Ne NR n N N Y N Y Y BL L,E Y N Y Y Bullous FDE NSAID
12 P12 22 M Nil Nil 94 0.9 0.3 16 21 111 7.4 4.4 20 0.4 135 5.2 Ne NR n Y N N Y N N F,PF N,L N N N N Acne . Erup Topical steroids
13 P13 22 F Nil Nil 94 0.4 0.1 17 22 104 7.4 4.3 22 0.8 140 4.2 97 Ne NR n N N Y N N Y PV,INT L,E N N Y Y FDE Paracetamol
14 P14 52 M Nil Nil 144 1 0.2 41 27 86 6.2 3.6 17 0.6 140 4.5 Ne NR n Y N Y N N N PV L N N N N Exanthem Unknown
15 P15 35 M T Nil 172 0.7 0.2 22 27 104 6.4 4.2 32 0.8 142 3.9 Ne NR FL N N N N N N F,PF L,N,E N N N N Acne . Erup Systemic Steroids
16 P16 40 F Nil Nil 59 0.3 0.1 68 72 254 7.2 3 20 1.2 131 5.7 105 24 Ne NR n N N Y N Y Y DENSE N,L Y Y N N SJS Carbamazepine
17 P17 75 M T Nil 73 1 0.5 21 23 104 5 2 14 0.7 136 3.5 96 Ne NR n N N N Y N Y PV,DBV L,E Y N Y Y Bullous FDE Ciprofloxacin
18 P18 55 F Nil Nil 85 0.2 0.1 28 22 74 6.4 3.8 66 1.4 135 4 101 27 Ne NR n N N Y N Y Y DENSE L Y Y N N SJS NSAID
19 P19 62 M Nil Nil 132 0.4 0.1 17 12 94 7.2 4.2 37 0.9 141 4 Ne NR n N N N Y N Y PV L N N Y Y FDE NSAID
20 P20 28 M T Nil 88 1.2 0.4 78 69 196 5.4 2.9 34 0.6 140 3.5 90 28 Ne NR n Y Y Y N N N PV,DBV L N N N N Erythroderma Carbamazepine
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           Histopathological examination                                                   Biochemical parameters       Others
21 P21 45 M Nil Nil 146 1.2 0.4 62 59 108 6.4 3.9 40 0.9 147 4 Ne NR n N N Y N N Y PV,INT L,E N N Y Y FDE Ciprofloxacin
22 P22 50 M Nil Nil 76 1.2 0.4 36 34 94 7 4.4 26 0.9 138 4.2 99 Ne NR n N N Y N N Y PV,INT L,E N N Y Y FDE paracetamol
23 P23 13 F Nil Nil 70 0.9 0.2 25 31 279 7 4 17 0.4 130 4.1 Ne NR n N N N N Y N PV,INT L,E N Y N N Exanthem Sodium valproate
24 P24 35 F Nil Nil 150 1.2 0.2 70 53 110 6.7 3 30 1 134 4.2 95 22 Ne NR FL N N Y N Y Y PV L,N,E Y Y N N TEN Unknown
25 P25 51 M Nil Nil 114 0.4 0.1 14 17 78 6.9 4.2 17 0.7 139 4.7 92 Ne NR n N N Y N N N PV,DBV L N N N N Exanthem Ciprofloxacin
26 P26 20 F Nil Nil 76 0.9 0.4 24 26 91 6.2 3.6 27 0.9 140 3.6 99 Ne NR n N N Y N N N PV,INT L N N N N Exanthem Phenytoin
27 P27 13 M Nil Nil 68 0.4 0.1 40 37 249 6.9 4.3 12 0.5 142 4.6 Ne NR n N N Y N Y N PV,INT L,E N Y N N EMF NSAID
28 P28 16 F Nil Nil 49 8.4 4.2 335 1296 277 4.9 2.6 61 1.1 132 4 97 25 Ne NR HM Y N Y N Y Y PV L,E N Y N N DRESS Phenytoin/Lamotrigine
29 P29 21 M Nil Nil 60 0.9 0.1 16 16 90 5.4 2.6 60 1.4 128 4.8 96 24 Ne NR HSM N N Y N N N PV N,L N Y N N Exanthem Arterolane+Piperaquine
30 P30 27 M Nil Nil 111 0.7 0.1 14 12 89 6 3.7 36 1 135 4 99 28 Ne NR n N N Y N Y Y PV,INT L,N,E Y Y N N SJS Cotrimoxazole
31 P31 20 M T Nil 96 0.6 0.2 16 14 58 7.3 2.6 35 1.1 130 3.9 Ne NR n Y N N N N N F,PF N,L N N N N Acne . Erup CTP  drug/Steroids
32 P32 66 F Pr Pr 325 0.3 0.1 91 205 78 7.3 3.1 205 5.1 127 5 98 25 Ne NR FL N N Y N Y Y INT L,E Y Y Y Y Bullous FDE Unknown
33 P33 61 M Nil Nil 127 0.8 0.3 92 78 662 4.5 2.4 64 1.4 129 4.3 105 23 Ne NR n N N Y N Y Y PV,INT L,N,E Y Y N N TEN Phenytoin
34 P34 68 F Nil T 211 1.2 0.4 30 36 121 6 3.4 42 1.3 147 4.7 Ne NR FL N N Y N N Y PV,INT L,E Y N Y Y Bullous FDE NSAID
35 P35 65 F Nil Nil 113 0.6 0.3 24 22 71 4.8 2.5 47 0.5 134 3.8 102 Ne NR n Y N N N Y N PV,DBV L,E N Y N N Exanthem Paracetamol
36 P36 14 M Nil Nil 88 1.3 0.8 39 34 46 6.5 3.6 58 1.5 163 4 99 27 Ne NR n N N Y N Y Y PV,INT L,N,E N Y Y N SJS/TEN Carbamazepine
KEY TO MASTERCHART 
 
Ad   – Adequate  
BL   – Band like 
Bl   – Beau’s lines 
CTP   –  Chemotherapeutic drug 
D   – Decreased 
DBV   – Dilated blood vessel 
DRESS  – Drug reaction with eosinophilia and systemic symptoms 
E   – Eosinophils 
EMF   – Erythema multiforme 
Eo   – Eosinophilia 
F   – Female 
F   – Follicular 
FDE   – Fixed drug eruption 
FL   – Fatty liver 
GBFDE  – Generalised bullous fixed drug eruption 
H   – Hypochromic 
HA   – Hyperpigmented annular lesions 
HM   –  Hepatomegaly 
HSM   – Hepatospleenomegaly 
I   – Increased 
INT   – Interstitial 
M   – Male 
Mi   – Microcytic 
N   – Neutrophils 
N   – No 
n   – Normal 
Ne   – Negative 
NR   – Non reactive 
NSAID  – Non steroidal anti inflammatory drugs 
OCP   – Oral contraceptive pills 
P   – Present 
P   – Purpura 
PA   – Periadnexal 
PF   – Perifollicular 
PV   – Perivascular 
S   – Scaling 
SGOT  – Serum glutamate oxaloacetate transferase 
SGPT  – Serum glutamate pyruvate transferase 
SJS   – Steven Johnson syndrome 
T   – Trace 
TEN   – Toxic epidermal necrosis 
TL   – Target lesions 
USG   – Ultrasonogram 
VCTC  – Voluntary counseling & testing centre 
VDRL  – Venereal disease research laboratory 
Y   – Yes  
 
  
PROFORMA 
 
Adverse cutaneous drug reactions –  A clinicopathological study 
 
Case no : 
 
Name :      Age :   Sex : M/F 
Address  : 
Occupation : 
Date of patient reporting to OPD /casualty : 
Date of admission (if admitted): 
 
Presenting complaints : 
Date of onset of skin lesions : 
Site of onset of skin lesions : 
Distribution of skin lesions : 
Other symptoms associated with skin lesions : 
Mucosal involvement : Y/N 
If yes  (site ):  
Constitutional symptoms : Y/N 
If yes ( symptom ) : 
Date of onset of illness for which treatment taken : 
Type of illness : 
Duration of illness : 
Treatment taken on date : 
Drugs taken : before / after constitutional symptoms 
H/o any native medications : 
Possible offending drug : 
Time interval between drug intake and onset of skin lesions : 
 
Past history : 
Any illness : Y/N 
Nature of illness : 
If yes (drugs taken previously and at present for the disease) : 
Any recent change of drug : 
Any drug reactions in the past :Y/N 
If yes (mention the drug ) : 
Type of skin lesion: 
Duration of illness : 
Treatment taken : 
Whether admitted : 
 
Personal history :  
Any addiction :  
 Iv drug abuse : 
 
Family history : 
H/o of drug reaction    : Y/N 
If yes (details )    : 
H/o collagen vascular disorders  : Y/N 
If yes ( details ) : 
 
General examination : 
Build and nourishment : 
Pallor /clubbing /cyanosis/lymphadenopathy/jaundice/pedal edema 
Pulse rate :       BP : 
Respiratory rate :     Temp : 
I/O chart : 
 
Systemic examination :  
CVS :       RS : 
ABDOMEN :      CNS :   
Dermatological Examination : 
Morphology of skin lesions: 
Sites affected ( % BSA ) : 
Mucosal lesions : 
Scalp and hair : 
Nails : 
Palms and soles : 
 Lab investigations : 
Blood R/E : 
Hb :    TC:  DC:    ESR: 
Platelet count : 
Absolute eosinophil count : 
Peripheral smear : 
Urine R/E : Alb -    sugar – 
Random blood sugar : 
Liver function tests : 
Renal function tests : 
Serum electrolytes : 
VCTC :     VDRL : 
USG Abdomen : 
Skin biopsy report : 
 
Final diagnosis: 
Treatment : 
 
 
 
  
INFORMATION SHEET 
 
TITLE :  “CLINICO PATHOLOGIAL STUDY OF ADVERSE CUTANEOUS 
DRUG REACTIONS” 
 
Name of Investigator : Dr.L.BALAMURUGAN   
Name of Participant : 
 
Purpose of Research : The purpose of this study is to analyse the incidence, various 
drugs causing adverse cutaneous drug reactions, clinical pattern of the disease and the 
role of  blood investigations and skin biopsy in assessing the severity of the disease 
 
Study Design  : Prospective Study 
 
Study Procedures :  In this study history of patient will be taken, examination and 
routine blood investigations,VCTC and VDRL will be done. Biopsy of  lesional skin will 
be done. Ultrasound of the abdomen, if needed will be done. The patients are then 
advised regarding avoidance of offending drug in future, and will be treated with 
emollients,topical or systemic drugs according to their need. 
 
Possible Risks : No risks to the patient 
 
Possible benefits : 
 
To patient : Any offending drug  will be detected and the patient is provided with any of 
the above mentioned treatments. 
 
To doctor & to other people :  The results of the study will help in confirming the role 
of drugs in the causation of the disease and emphasis the importance of avoidance of 
such drugs if alternative drugs available , in preventing such adverse reactions in the 
future. 
 
Confidentiality of the information obtained from you : The privacy of the patients in 
the research will be maintained throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable information will be 
shared 
 
Can you decide to stop participating in the study : Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to withdraw at 
any time 
 
How will your decision to not participate in the study affect you : Your decision will 
not result in any loss of  benefits to which you are otherwise entitled. 
 
 
Signature of Investigator                Signature of  Participant 
Date : 
Place : 
  
PATIENT CONSENT FORM 
 
 
Title of the study:  : “CLINICO PATHOLOGICAL STUDY OF ADVERSE 
CUTANEOUS DRUG REACTIONS” 
 
Name of the Principal investigator: Dr.L.BALAMURUGAN. 
 
 Name of the Institution: Rajiv Gandhi Government General Hospital,Chennai 
 
  Patient’s Name :  
  Patient’s Age :  
  OutPatient No  : 
 
 
 
            I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction.  
           I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected.  
           I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not need 
my permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study.  
           I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my health or 
well being or any unexpected or unusual symptoms.  
         I hereby consent to participate in this study 
 
 
 
         I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests and to 
undergo treatment. 
 
 
 
Signature/thumb impression 
Patient’s Name and Address: 
 
Signature of Investigator 
Study Investigator’s Name: 
Dr.L.Balamurugan  
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